業 績論文数・IF(impact factor)値・CI(Citation index)値
OA
時期
19922024
19922013
20142024

論文数IF

IF/論文数CI

CI/論文数3071453.9

4.74

2880

9.38

106

645.8

6.09

1838

17.3

201

808.1

4.02

1042

5.18

論文数

IF

IF/論文数CI

CI/論文数

10

40.7

4.07

127

12.7

1

x

x

5

X

9

30.7

3.41

122

13.6

論文数

IF

IF/論文数CI

CI/論文数

36

80.3

2.23

71

1.97

11

33.6

3.05

40

3.63

26

48.3

1.86

31

1.19

論文数

IF

IF/論文数CI

CI/論文数

354

1576.5

4.45

3078

8.69

review
時期
19922024
19922013
20142024
CR
時期
19922024
19922013
20142024
Total
時期
19922024

1992201320142024

118

679.4

5.78

1883

16

236

887.1

3.76

1195

5.06

2014-2024 年は教授就
任後Original Articles

I.

8. Shinohara N, Ogiso Y, Kuzumaki N, Mullauer L, Katabami M, Togashi M, Koyanagi T:
Circumvention of cisplatin resistance in H-ras transformed-NIH/3T3 cells by suppressor
mutant of H-ras. Int. J. Oncol. 1, 93-96, 1992 [IF 5.2, CI 0]
9. Togashi M, Shinohara N, Toyota K, Koyanagi T, Maru A, Fujieda J, Kawakura K, Nishida
T, Ohhashi N: Prophylactic chemotherapy for primary and recurrent superficial bladdercancer: preliminary results. The Hokkaido University Bladder Cancer Collaborating Group.
Cancer Chemother. Pharmacol. 30, 21-25, 1992 [IF 3.0, CI 0]
10. Shinohara N, Liebert M, Wedemeyer G, Chang JHC, Grossman HB:

Evaluation ofmultiple drug resistance in human bladder cancer cell lines. J. Urol. 150, 505-509, 1993
[IF 6.6, CI 8]
11. Shinohara N, Ogiso Y, Arai T, Takami S, Nonomura K, Koyanagi T, Kuzumaki N:
Differential Na+, K+-ATPase activity and cisplatin sensitivity between transformants
induced by H-ras and those induced by K-ras. Int. J. Cancer 58, 672-677, 1994 [IF 6.4, CI
3]
12. Shinohara N, Nonomura K, Takakura F, Hamada M, Grossman HB, Koyanagi T:
Expression of multidrug resistance gene product (P-glycoprotein) in transitional cell
carcinomas of the upper urinary tract. Eur. Urol. 26, 327-333, 1994. [IF 23.4, CI 0]
13. Shinohara N, Nonomura K, Tanaka M, Nagamori S, Takakura F, Seki T, Koyanagi T,
Togashi M, Maru A: Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin,
and pirarubicin) for primary superficial bladder cancer. The Hokkaido University Bladder
Cancer Collaborating Group. Cancer Chemothe. Pharmacol. 35, 41-45, 1994 [IF 3.0, CI 3]
14. Park J, Shinohara N, Liebert M, Noto L, Flint A, Grossman HB: P-glycoprotein expressionin bladder cancer. J. Urol. 151, 43-46, 1994 [IF 6.6, CI 3]
15. Arai T, Sagara M, Shinohara N : Changes of cytosolic enzyme activities in H-ras
transformed NIH/3T3 cells. Bull Nippon Vet. Anim. Sci. Univ. 43, 49-51, 1994 [IF NA, CI
0]16. Shinohara N, Nonomura K, Harabayashi T, Togashi M, Nagamori S, Koyanagi T: Nephronsparing surgery for renal cell carcinoma in von Hippel-Lindau disease. J. Urol. 154, 20162019, 1995 [IF 6.6, CI 2]
17. Kondo K, Sakai N, Kaneko S, Kobayashi K, Hosaka M, Ito S, Fujii S, Yamamoto I, Kim I,
Miyagami M, Shidara N, Shinohara N, Koyanagi T, Kato N, Yamanaka H, Kurata JI,
Fujioka M, Nakatsu H, Shimazaki J, Yoshida J, Sugita K, Hirao Y, Okajima E, Tanagawa T,
Sato S, Fujino H, Nagata M, Kanayama H, Kagawa S, Yamashita T, Furuta T, Saito Y, Hara
T, Murayama KI, Hiratsuka Y, Shimosegawa T, Maekawa M, Miyahara S, Murata K,
Kawamura J, Ogawa O, Yoshida O, Miki M, Takeda N, Tanaka R, Kinoshita H, Sekine T,
Yokota J, Kakizoe T, Kogawa T, Kanno H, Yao M, Shuin T: Germline mutations in the vonHippel-Lindau disease (VHL) gene in Japanese VHL. Hum. Mol. Genet. 4(12), 2233-2237,
1995 [IF 5.1, CI ?]18. Tanaka M, Mullauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, Harabayashi T, Shinohara
N, Koyanagi T, Kuzumaki N: Gelsolin: a candidate for suppressor of human bladder cancer.
Cancer Res. 55, 3228-3232, 1995 [IF 11.2, CI 40]
19. Demura T, Shinohara N, Tanaka M, Enami N, Chiba H, Togashi M, Ohashi N, Nonomura
K, Koyanagi T: The Proportion of free to total prostate specific antigen: A method of
detecting prostate carcinoma. Cancer 77, 1137-1143, 1996 [IF 6.2, CI 4]
20. Shinohara N, Ogiso Y, Tanaka M, Sazawa A, Harabayashi T, Koyanagi T: The significanceof ras guanine nucleotide exchange factor, son of sevenless protein, in renal cell carcinoma
cell lines. J. Urol. 158, 908-911, 1997 [IF 6.6, CI 2]
21. Shinohara N, Demura T, Matsumura K, Toyoda K, Kashiwagi A, Nagamori S, Ohmuro H,
Ohzono S, Koyanagi T: 5-Fluorouracil and low-dose recombinant interferon a-2a in patientswith hormone-refractory adenocarcinoma of the prostate. Prostate 35, 56-62, 1998 [IF 2.8,
CI 1]
22. Shinohara N, Hioka T, Harabayashi T, Demura T, Kashiwagi A, Nagamori S, Koyanagi T:
Treatment of metastatic nonseminomatous germ cell tumors of the testis: significance of theinternational consensus prognostic classification as a prognostic factor-based staging system.
Int. J. Urol. 5(6), 562-567, 1998. [IF 2.6, CI 0]

23. Tanaka M, Sazawa A, Shinohara N, Kobayashi Y, Fujioka Y, Koyanagi T, Kuzumaki N:
Gelsolin gene therapy by retrovirus producer cells for human bladder cancer in nude mice.
Cancer Gene Ther. 5, 482-487, 1999 [IF 6.4, CI 1]
24. Watanabe T, Shinohara N, Sazawa A, Kobayashi Y, Ogiso Y, Kimura T, Takeguchi M,
Yasuda J, Hashimoto A, Koyanagi T, Kuzumaki N: Suppressive effects of dominant negativeras mutant N116Y on transformed phenotypes of human bladder cancer cells. Cancer Letter
149, 195-202, 2000 [IF 9.7, CI 2]
25. Kitta T, Shinohara N, Shirato H, Otsuka H, Koyanagi T: The treatment of chronic radiation
proctitis with hyperbaric oxygen in patients with prostate cancer. BJU Int. 85(3), 372-374,
2000 [IF 4.5, CI 6]
26. Kitamura K, Shirato H, Suzuki K, Shinohara N, Demura T, Harabayashi T, Nishioka T,
Kagei K, Takayama N, Shinno Y, Kawakura K, Koyanagi T, Miyasaka K.: The relationshipbetween technical parameters of external beam radiation therapy and complications for
localized prostate cancer. Jpn. J. Clin. Oncol. 30(5), 225-229, 2000 [IF 2.4, CI 1]
27. Watanabe T, Shinohara N, Moriya K, Sazawa A, Kobayashi Y, Ogiso Y, Takiguchi M,
Yasuda J, Koyanagi T, Kuzumaki N, Hashimoto A: Significance of the Grb2 and son ofsevenless (Sos) proteins in human bladder cancer cell lines. IUBMB Life 49(4), 317-320,
2000 [IF 4.6, CI 11]
28. Shirato H, Shimizu S, Kitamura K, Nishioka T, Kagei K, Hashimoto S, Aoyama H, Kunieda
T, Shinohara N, Dosaka-Akita H, Miyasaka K: Four-dimensional treatment planning andfluoroscopic real-time tumor tracking radiotherapy for moving tumor. Int. J. Radiat. Oncol.
Biol. Phys. 48(2), 435-442, 2000 [IF 7.0, CI 69]
29. Shimizu S, Shirato H, Kitamura K, Shinohara N, Harabayashi T, Tsukamoto T, Koyanagi T,
Miyasaka K: Use of an implanted marker and real-time tracking of the marker for the
positioning of prostate and bladder cancers. Int. J. Radiat. Oncol. Biol. Phys. 48(5), 15911597, 2000 [IF 7.0, CI 30]
30. Watanabe T, Shinohara N, Sazawa A, Harabayashi T, Ogiso Y, Koyanagi T, Takiguchi M,
Hashimoto A, Kuzumaki N, Yamashita M, Tanaka M, Grossman HB, Benedict WF: Animproved intravesical model using human bladder cancer cell lines to optimize gene andother therapies. Cancer Gene Ther 7(12), 1575-1580, 2000. [IF 6.4, CI 24]
31. Shinohara N, Harabayashi T, Sato S, Hioka T, Tsuchiya K, Koyanagi T: Impact of nephronsparing surgery on quality of life in patients with localized renal cell carcinoma. Eur. Urol.
39(1), 114-119, 2001 [IF 23.4, CI 15]
32. Nonomura K, Koyama T, Kakizaki H, Murakumo M, Shinohara N, Koyanagi T: Testicularsparing surgery for the prepubertal testicular tumor. Experience of two cases with large cell
calcifying Sertoli cell tumors.

Eur. Urol. 40(6), 699-704, 2001 [IF 23.4, CI 5]

33. Watanabe T, Shinohara N, Sazawa A, Takimoto M, Hashimoto A, Koyanagi T, Kuzumaki
N: Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using adominant negative H-ras mutant. Int. J. Cancer 92(5), 712-717, 2001 [IF 6.4, CI 3]
34. Kitamura K, Shirato H, Seppenwoolde Y, Onimaru R, Oda M, Fujita K, Shimizu S,
Shinohara N, Harabayashi T, Miyasaka K: Three-dimensional intrafractional movement of
prostate measured during real-time tumor-tracking radiotherapy in supine and prone
treatment positions. Int. J. Radiat. Oncol. Biol. Phys. 53(5), 1117-1123, 2002 [IF 7.0, CI 49]
35. Kitamura K, Shirato H, Shimizu S, Shinohara N, Harabayashi T, Shimizu T, Kodama Y,
Endo H, Onimaru R, Nishioka S, Aoyama H, Tsuchiya K, Miyasaka K: Registration
accuracy and possible migration of internal fiducial gold marker implanted in prostate andliver treated with real-time tumor-tracking radiation therapy (RTRT). Radiother. Oncol.
62(3), 275-281, 2002 [IF 5.7, CI 30]
36. Sazawa A, Watanabe T, Tanaka M, Haga K, Fujita H, Harabayashi T, Shinohara N,
Koyanagi T, Kuzumaki N: Adenovirus mediated gelsolin gene therapy for orthotopic human
bladder cancer in nude mice. J Urol 168(3), 1182-1187, 2002 [IF 6.6 CI 4]
37. Kato T, Tsukamoto E, Kuge Y, Takei T, Shiga T, Shinohara N, Katoh C, Nakada K, Tamaki
N: Accumulation of [(11)C]acetate in normal prostate and benign prostatic hyperplasia:
comparison with prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 29(11), 1492-1495, 2002
[IF 9.1 CI 39]
38. Suzuki S, Shinohara N, Harabayashi T, Taniguchi A, Haga K, Sato S, Sakamoto K,

Koyanagi T: Complications of bacillus Calmette-Guerin therapy in superficial urothelial
cancer: clinical analysis and implications. Int. J. Clin. Oncol. 7(5), 289-293, 2002 [IF 3.3
CI 1]
39. Shirato H, Harada T, Harabayashi T, Hida K, Endo H, Kitamura K, Onimaru R, Yamazaki K,
Kurauchi N, Shimizu T, Shinohara N, Matsushita M, Dosaka-Akita H, Miyasaka K.:
Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for
precise setup and real-time tumor tracking in radiotherapy. Int. J. Radiat. Oncol. Biol.
Phys. 56(1), 240-247, 2003 [IF 7.0 CI 88]
40. Kitamura K, Shirato H, Shinohara N, Harabayashi T, Onimaru R, Fujita K, Shimizu S,
Nonomura K, Koyanagi T, Miyasaka K.: Reduction in acute morbidity using
hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time
tumor-tracking system for prostate cancer: preliminary results of a phase I/II study. Cancer J.
9(4), 268-276, 2003 [IF 2.2 CI 13]
41. Harabayashi T, Shinohara N, Katano H, Nonomura K, Shimizu T, Koyanagi T: Managementof renal angiomyolipomas associated with tuberous sclerosis complex. J. Urol. 171(1), 102105, 2004 [IF 6.6 CI 23]
42. Sato S, Shinohara N, Suzuki S, Harabayashi T, Koyanagi T: Multiple primary malignancies
in Japanese patients with renal cell carcinoma. Int. J. Urol. 11(5), 269-275, 2004 [IF 2.6 , CI
19]
43. Taniguchi A, Tajima T, Nonomura K, Shinohara N, Mikami A, Koyanagi T: Expression ofvascular endothelial growth factor and its receptors Flk-1 and Flt-1 during the regenerationof autotransplanted adrenal cortex in the adrenalectomized rat. J. Urol. 171(6), 2445-2449,
2004 [IF 6.6 CI 3]
44. Takahashi A, Tsukamoto T, Tobisu K, Shinohara N, Sato K, Tomita Y, Komatsubara S,
Nishizawa O, Igarashi T, Fujimoto H, Nakazawa H, Komatsu H, Sugimura Y, Ono Y, Kuroda
M, Ogawa O, Hirao Y, Hayashi T, Tsushima T, Kakehi Y, Arai Y, Ueda S, Nakagawa M:
Radical cystectomy for invasive bladder cancer: results of multi-institutional pooled analysis.
Jpn. J. Clin. Oncol. 34(1), 14-19, 2004 [IF 2.4 CI 9]
45. Chen Q, Shinohara N, Abe T, Watanabe T, Nonomura K, Koyanagi T.: Significance ofCOX-2 expression in human renal cell carcinoma cell lines. Int J Cancer. 108(6), 825-32,
2004 [IF 6.4 CI 13]
46. Furuno T, Demura T, Kaneta T, Gotoda H, Muraoka S, Sato T, Nagamori S, Shinohara N,
Koyanagi T: Difference of cancer core distribution between first and repeat biopsy: In
patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy.
Prostate 58(1), 76-81, 2004 [IF 2.8 CI 21]
47. Suzuki S, Shinohara N, Harabayashi T, Sato S, Abe T, Koyanagi T: Impact of adjuvant
systemic chemotherapy on postoperative survival in patients with high-risk urothelial cancer.
Int J. Urol. 11(7), 456-460, 2004 [IF 2.6 CI 6]
48. Haga K, Fujita H, Nomoto M, Sazawa A, Nakagawa K, Harabayashi T, Shinohara N,
Takimoto M, Nonomura K, Kuzumaki N:

Gelsolin gene silencing involving unusual

hypersensitivities to dimethylsulfate and KMnO(4) in vivo footprinting on its promoter
region. Int. J. Cancer 111(6), 873-880, 2004 [IF 6.4, CI 4]
49. Chen Q, Shinohara N, Abe T, Harabayashi T, Nonomura K: Impact of cyclooxygenase-2
gene expression on tumor invasiveness in a human renal cell carcinoma cell line. J. Urol. 172(6), 2153–2157, 2004 [IF 6.6 CI 9]
50. Hachiya T, Akakura K, Saito S, Shinohara N, Sato K, Harada M, Kato T, Okada K: A
retrospective study of the treatment of locally advanced prostate cancer by six institutions ineastern and north-eastern Japan. BJU Int. 95(4), 534-540. 2005 [IF 4.5 CI 4]
51. Demura T, Hioka T, Furuno T, Kaneta T, Gotoda H, Muraoka S, Sato T, Mochizuki T,
Nagamori S, Shinohara N: Differences in tumor core distribution between palpable andnonpalpable prostate tumors in patients diagnosed using extensive transperineal ultrasoundguided template prostate biopsy. Cancer 103(8), 1826-1832, 2005 [IF 6.2 , CI 16]
52. Minami K, Yanagawa Y, Iwabuchi K, Shinohara N, Harabayashi T, Nonomura K, Onoe K:
Negative feed back regulation of T helper type 1 (Th1)/Th2 cytokine balance via dendritic
cell and natural killer T cell interactions. Blood 106(5), 1685-1693, 2005 [IF 20.3 , CI 11]
53. Shinohara N, Harabayashi T, Suzuki S, Nagao K, Seki H, Murakumo M, Mitsuhashi K,
Demura T, Nagamori S, Matsuyama H, Naito K, Nonomura K: Salvage chemotherapy withpaclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received
prior cisplatin-based therapy. Cancer Chemother. Pharmacol. 58(3), 402-407, 2006 [IF 3, CI
10]
54. Abe T, Tada M, Shinohara N, Okada F, Itoh T, Hamada J, Harabayashi T, Chen Q, Moriuchi
T, Nonomura K.：Establishment and characterization of human urothelial cancer xenografts
in severe combined immunodeficient mice. Int. J. Urol. 13(1), 47-57, 2006 [IF 2.6 CI 10]
55. Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, Shinohara N, Shinka T,
Tachibana M, Naito S, Hirao Y: BCG Tokyo 172 Strain Study Group. Sustained prophylactic
effect of intravesical bacille Calmette-Guerin for superficial bladder cancer: a smoothedhazard analysis in a randomized prospective study. Urology 67(3), 545-549, 2006 [IF 2.1 CI
5]
56. Toyoda Y, Shinohara N, Harabayashi T, Abe T, Akino T, Sazawa A, Nonomura K: Survival
and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur.
Urol. 52(1), 163-168, 2007 [IF 23.4 CI 21]
57. Higashiyama H, Harabayashi T, Shinohara N, Chuma M, Hige S, Nonomura K.:
Reactivation of Hepatitis in a Bladder Cancer Patient Receiving Chemotherapy. Int. Urol.
Nephrol. 39(2), 46 1-463, 2007 [IF２ CI 3]

58. Abe T, Shinohara N, Harabayashi T, Sazawa A, Maruyama S, Suzuki S, Nonomura K.：
Impact of Multimodal Treatment on Survival in Patients with Metastatic Urothelial Cancer.
Eur. Urol. 52 (4), 1106-1113, 2007 [IF 23.4, CI 23]
59. Abe T, Shinohara N, Harabayashi T, Sazawa A, Suzuki S, Kawarada Y, Nonomura K.：
Postoperative inguinal hernia after radical prostatectomy for prostate cancer. Urology 69(2),326-329, 2007 [IF 2.1, CI 22]
60. Kakehi Y, Kamoto T, Shiraishi T, Ogawa O, Suzukamo Y, Fukuhara S, Saito Y, Tobisu K,
Kakizoe T, Shibata T, Fukuda H, Akakura K, Suzuki H, Shinohara N, Egawa S, Irie A, Sato
T, Maeda O, Meguro N, Sumiyoshi Y, Suzuki T, Shimizu N, Arai Y, Terai A, Kato T,
Habuchi T, Fujimoto H, Niwakawa M: Prospective Evaluation of Selection Criteria for
Active Surveillance in Japanese Patients with Stage T1cN0M0 Prostate Cancer. Jpn. J. Clin.

Oncol. 38(2), 122-128, 2008 [IF 2.4, CI 31]
61. Miyajima N, Maruyama S, Bohgaki M, Kano S, Shigemura M, Shinohara N, Nonomura K,
Hatakeyama S: TRIM68 regulates ligand-dependent transcription of androgen receptor inprostate cancer cells. Cancer Res. 68 (9), 3486-3494, 2008 [IF 11.2, CI 27]
62. Abe T, Shinohara N, Harabayashi T, Sazawa A, Ishikawa S, Kubota K, Matsuno Y, Osawa
T, Shibata T, Shinno Y, Kamoto S, Minami K, Sakashita S, Takeuchi I, Kumagai A, Mori T,
Togashi M, Nonomua K: The Role of Lymph Node Dissection in the Treatment ofUpper
Urinary Tract Cancer: Multi-institutional study. BJU Int. 102(5), 576-80, 2008

[IF 4.5 , CI

13]
63. Abe T, Shinohara N, Tada M, Harabayashi T, Sazawa A, Maruyama S, Moriuchi T, Takeda
K, Nonomura K: Infiltration of Epstein-Barr virus-harboring lymphocytes occurs in a large
subset of bladder cancers. Int. J. Urol. 15(5), 429-434, 2008 [IF 2.6, CI 4]
64. Katoh N, Onimaru R, Sakuhara Y, Abo D, Shimizu S, Taguchi H, Watanabe Y, Shinohara N,
Ishikawa M, Shirato H: Real-time tumor-tracking radiotherapy for adrenal tumors.
Radiother. Oncol. 87(3), 418-424, 2008 [IF 5.7, CI 20]
65. Ito K, Nakazawa H, Marumo K, Ozono S, Igarashi T, Shinohara N, Fukuda M, Tsushima T,
Naito S, Hayakawa M: Risk factors for ipsilateral adrenal involvement in renal cell
carcinoma. Urology 72(2), 354-358, 2008 [IF 2.1, CI 2]
66. Hinotsu S, Akaza H, Miki T, Fujimoto H, Shinohara N, Kikuchi E, Mizutani Y, Koga H,
Okajima E, Okuyama A; Bladder cancer develops 6 years earlier in current smokers: analysisof bladder cancer registry data collected by the cancer registration committee of the Japanese
Urological Association. Int. J. Urol. 16(1), 64-69, 2009 [IF 2.6 , CI 1]
67. Osawa T, Abe T, Shinohara N, Harabayashi T, Sazawa A, Kubota K, Matsuno Y, Shibata T,
Shinno Y, Kamota S, Minami K, Sakashita S, Kumagai A, Mori T, Nonomura K: Role oflymph node density in predicting survival of patients with lymph node metastases afterradical cystectomy: A multi-institutional study. Int. J. Urol. 16(3), 274-278, 2009 [IF 2.6 ,CI 15]
68. Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M,

Miki T; the Cancer Registration Committee of the Japanese Urological Association: Clinicaloutcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on
registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological
Association. Int. J. Urol. 16(3), 279-286, 2009 [IF 2.6, CI 16]
69. Shinohara N, Kumagai A, Kanagawa K, Maruyama S, Abe T, Sazawa A, Nonomura K：
Multi-center phase II trial of combination therapy with meloxicam, a COX-2 inhibitor, andnatural interferon alfa for metastatic renal cell carcinoma. Jpn. J. Clin. Oncol. 39(11), 720726, 2009 [IF 2.4, CI 9]
70. Akino T, Hida K, Hida Y, Tsuchiya K, Freedman D, Muraki C, Ohga N, Matsuda K,
Akiyama K, Harabayashi T, Shinohara N, Nonomura K, Klagsbrun M, Shindoh M:
Cytogenetic Abnormalities of Tumor-Associated Endothelial Cells in Human Malignant
Tumors. Am. J. Pathol. 175(6), 2657-2667, 2009 [IF 6.0, CI 94]
71. Abe T, Shinohara N, Harabayashi T, Sazawa A, Akino T, Ishikawa S, Kubota K, Matsuno Y,
Osawa T, Shibata T, Toyoda Y, Shinno Y, Kamota S, Minami K, Sakashita S, Kumagai A,
Takada N, Togashi M, Sano H, Mori T, Nonomura K: Pathologic characteristics and clinicalcourse of bladder tumor developing after nephroureterectomy. BJU Int. 105(8), 1102-1106,
2010 [IF 4.5, CI 3]
72. Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, Takahashi
A, Maruyama R, Saika T, Hoshi S, Nagao K, Yamamoto S, Sugimura I, Uemura H, Koga S,
Takahashi M, Ito F, Ozono S, Terachi T, Naito S, Tomita Y: Prognosis of Japanese Metastatic
Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463
Patients. Eur. Urol. 57(2), 317-325, 2010 [IF 23.4, CI 72]
73. Uemura H, Shinohara N, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, Mugiya S, Miki T,
Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H: A Phase II
Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into
the Treatment, Efficacy and Safety. Jpn. J. Clin. Oncol. 40(3), 194-202, 2010 [IF 2.4, CI 56]
74. Yokomizo A, Koga H, Shinohara N, Miyahara T, Machida N, Hasui Y, Uozumi J,
Nishiyama K, Satoh F, Sakai H, Naito S: Skeletal-related events in urological cancer patientswith bone metastasis: A multicenter study in Japan. Int. J. Urol. 17(4), 332-336, 2010 [IF
2.6, CI 4]

75. Oishi Y, Nagai S, Yoshida M, Fujisawa SI, Sazawa A, Shinohara N, Nonomura K, Matsuno
K, Shimizu C.: Mutation analysis of the SDHB and SDHD genes in pheochromocytomas andparagangliomas: identification of a novel nonsense mutation (Q168X) in the SDHB gene.
Endocr. J. 57(8), 745-750, 2010 [IF 2.0, CI 4]
76. Tsuchiya K, Hida K, Hida Y, Muraki C, Ohga N, Akino T, Kondo T, Miseki T, Nakagawa K,
Shindoh M, Harabayashi T, Shinohara N, Nonomura K, Kobayashi M: Adrenomedullin
antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on
tumor endothelial cells and endothelial progenitor mobilization. Int. J. Oncol. 36(6), 13791386, 2010 [IF 5.2, CI 20]
77. Sumiyoshi Y, Hashine K, Kakehi Y, Yoshimura K, Satou T, Kuruma H, Namiki S, Shinohara
N: Dietary administration of mushroom mycelium extracts in patients with early stage
prostate cancers managed expectantly: A phase II study. Jpn. J. Clin. Oncol. 40(10), 967-972,
2010 [IF 2.4, CI 4]
78. Ishikawa S, Abe T, Shinohara N, Harabayashi T, Sazawa A, Maruyama S, Kubota K,
Matsuno Y, Osawa T, Shinno Y, Kumagai A, Togashi M, Matsuda H, Mori T, Nonomura K:
Impact of Diagnostic Ureteroscopy on Intravesical Recurrence and Survival in Patients with
Upper Urinary Tract Cancer. J. Urol. 184(3), 883-888, 2010 [IF 6.6, CI 28]
79. Tomita Y, Shinohara N, Yuasa T, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Uemura H,
Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H: Overall
survival and updated results from a Phase II Study of Sunitinib in Japanese Patients with
Metastatic Renal Cell Carcinoma. Jpn. J. Clin. Oncol. 40(12). 1166-1172, 2010 [IF 2.4, CI
50]
80. Tatsugami K, Kuroiwa K, Kamoto T, Nishiyama H, Watanabe J, Ishikawa S, Shinohara N,
Sazawa A, Fukushima S, Naito S: Evaluation of narrow-band imaging as a complementary
method for the detection of bladder cancer. J. Endourol. 24(11), 1807-1811, 2010 [IF 2.7, CI
32]
81. Abe T, Shinohara N, Muranaka M, Sazawa A, Maruyama S, Osawa T, Harabayashi T,
Kubota K, Matsuno Y, Shibata T, Toyada Y, Shinno Y, Minami K, Sakashita S, Kumagai A,
Takada N, Togashi M, Sano H, Mori T, Nonomura K.: Role of lymph node dissection in thetreatment of urothelial carcinoma of the upper urinary tract: Multi-institutional relapse
analysis and immunohistochemical re-evaluation of negative lymph nodes. Eur. J. Surg.
Oncol. 36(11), 1085-1091. 2010 [IF 3.8, CI 23]
82. Naito S, Eto M, Shinohara N, Tomita Y, Fujisawa M, Namiki M, Nishikido M, Usami M,
Tsukamoto T, Akaza H: Multicenter phase II trial of S-1 in patients with cytokine-refractory
metastatic renal cell carcinoma. J. Clin. Oncol. 28, 5022-5028, 2010 [IF 45.3 , CI 1]
83. Tsukamoto T, Shinohara N, Tsuchiya N, Hamamoto Y, Maruoka M, Fujimoto H, Niwakawa
M, Uemura H, Usami M, Terai A, Kanayama H, Sumiyoshi Y ,Eto M, Tajima T, Kasuga A,
Fujita Y, Kay A, Akaza H：Phase III trial of everolimus in metastatic renal cell carcinoma:
subgroup analysis of Japanese patients From RECORD-1. Jpn. J. Clin. Oncol. 41, 17-24,
2010 [IF 2.4, CI 17]
84. Okajima E, Fujimoto H, Mizutani Y, Kikuchi E, Koga H, Hinotsu S, Shinohara N, Miki T:
the Cancer Registration Committee of the Japanese Urological Association.：Cancer deathfrom non-muscle invasive bladder cancer: Report of the Japanese Urological Association ofdata from the 1999-2001 registry in Japan. Int. J. Urol. 17(11) 905-912, 2010 [IF 2.6, CI 1]
85. Shinohara N, Takahashi M, Kamishima T, Ikushima H, Otsuka N, Ishizu A, Shimizu C,
Kanayama H, Nonomura K: The incidence and the mechanism of sunitinib-induced thyroid
atrophy in patients with metastatic renal cell carcinoma. Br. J. Cancer 104, 241-247, 2011
[IF 8.8, CI 17]
86. Miyao N, Naito S, Ozono S, Shinohara N, Masumori N, Igarashi T, Nakao M, Tsushima T,
Senga Y, Horie S, Kanayama HO, Tokuda N, Kobayashi M; Japanese Society of Renal
Cancer：Late Recurrence of Renal Cell Carcinoma: Retrospective and Collaborative Study of
the Japanese Society of Renal Cancer. Urology 77, 379-384, 2011 [IF 2.1, CI 32]
87. Abe T, Harabayashi T, Shinohara N, Sazawa A, Maruyama S, Sasaki H, Nonomura K.:
Outcome of Regional Lymph Node Dissection in Conjunction with Laparoscopic
Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract. J. Endourol.
25(5), 803-807, 2011 [IF 2.7, CI 2]
88. Shimizu S, Osaka Y, Shinohara N, Sazawa A, Nishioka K, Suzuki R, Onimaru R, Shirato
H.: Use of Implanted Markers and Interportal Adjustment with Real-Time Tracking

Radiotherapy System to Reduce Intrafraction Prostate Motion. Int J Radiat Oncol Biol Phys.
81(4), e393-399, 2011 [IF 7.0, CI 14]
89. Tomita Y, Uemura H, Fujimoto H, Kanayama H, Shinohara N, Nakazawa H, Imai K,
Umeyama Y, Ozono S, Naito S, Akaza H: Key predictive factors of axitinib (AG-013736)induced proteinuria and efficacy: a phase II study in Japanese patients with cytokinerefractory metastatic renal cell cancer. Eur. J. Cancer 47(17), 2592-2602, 2011 [IF 8.4, CI
51]
90. Maru S, Abe T, Shinohara N, Sazawa A, Maruyama S, Harabayashi T, Suzuki S, Nonomura
K: Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic
agents on the outcome of metastatic urothelial carcinoma: A retrospective study. Int J Urol
19(2), 110-116, 2012 [IF 2.6, CI 10]
91. Shinohara N, Abe T , Sazawa A , Maruyama S, Shindo J, Sato S, Suzuki S, Nonomura K:
Interferon-α-based immunotherapy in metastatic renal cell carcinoma patients with theprimary tumor in situ. Jpn. J. Clin. Oncol. 42(2), 113-119, 2012 [IF 2.4, CI 2]
92. Saito H, Matsuda T, Tanabe K, Kawauchi A, Terachi T, Nakagawa K Iwamura M, Shigeta M,
Naito S, Ito A, Machida J, Kawakita M, Kinoshita H, Shinohara N, Ioritani N, Seki T, andArai Y, on behalf of the Japanese Society of Endourology Laparoscopic Partial Nephrectomy
Study Group. Surgical and oncological outcomes of laparoscopic partial nephrectomy: aJapanese multi-institutional study of 1,375 patients. J. Endourol. 26(6), 652-659, 2012 [IF
2.7, CI 4]
93. Ohga N, Ishikawa S, Maishi N, Akiyama K, Hida Y, Kawamoto T, Sadamoto Y, Osawa T,

Yamamoto K, Kondoh M, Ohmura H, Shinohara N, Nonomura K, Shindoh M, Hida K:
Heterogeneity of Tumor Endothelial Cells: Comparison between Tumor Endothelial Cells
Isolated from Highly Metastatic and Low Metastatic Tumors. Am. J. Pathol. 180(3), 12941307, 2012 [IF 6.0, CI 73]

94. Maishi N, Ohga N, Hida Y, Akiyama K, Kitayama K, Osawa T, Onodera Y, Shinohara N,
Nonomura K, Shindoh M, Hida K: CXCR7: A novel tumor endothelial marker in renal cell
carcinoma. Pathol. Int. 62(5), 309-317, 2012 [IF 2.2, CI 39]
95. Yamamoto K, Ohga N, Hida Y, Maishi N, Kawamoto T, Kitayama K, Akiyama K, Osawa T,Kondoh M, Matsuda K, Onodera Y, Fujie M, Kaga K, Hirano S, Shinohara N, Shindoh M,
Hida K: Biglycan is a specific marker and an autocrine angiogenic factor of tumour
endothelial cells. Br. J. Cancer 106(6), 1214-1223, 2012 [IF 8.8, CI 55]
96. Osawa T, Ohga N, Hida Y, Kitayama K, Akiyama K, Onodera Y, Fujie M, Shinohara N,
Nonomura K, Shindoh M, Hida K: Prostacyclin receptor in tumor endothelial cells promotes
angiogenesis in an autocrine manner. Cancer Sci. 103(6), 1038-1044, 2012 [IF 5.7, CI 17]
97. Shinohara N, Nonomura K, Abe T, Maruyama S, Kamai T, Takahashi M, Tatsugami K,
Yokoi S, Deguchi T, Kanayama H, Oba K, Naito S: A new prognostic classification for
overall survival in Asian patients with previously untreated metastatic renal cell carcinoma.
Cancer Sci. 103 (9), 1695-1700, 2012 [IF 5.7, CI 20]
98. Mitsui T, Tanaka H, Harabayashi T, Moriya K, Maruyama S, Abe T, Sazawa A, Shinohara
N, Nonomura K: Changes in urodynamics and lower urinary tract symptoms after radical
prostatectomy: implications of preoperative detrusor. contractility. LUTS 2012; 4: 82-86,
2012 [IF 1.3, CI 0]
99. Abe T, Sazawa A, Harabauashi T, Shinohara N, Maruyama S, Nonomura K: Renal
hypothermia with ice slush in laparoscopic partial nephrectomy: the outcome of renal
function. J. Endourol. 26(11), 1483-1488, 2012 [IF 2.7, CI 6]
100.

Kuroda N, Tanaka A, Yamaguchi T, Kasahara K, Naruse K, Yamada Y, Chikai-Kubota

K, Shinohara N, Nagashima Y, Mikami S, Oya M, Hamashima T,, Michal M, Hes O:
Chromophobe renal cell carcinoma, oncocytic variant: A proposal of a new variant and acritical diagnostic pitfall in diagnosing renal oncocytic tumors. Med. Mol. Morphol. 46(1),49-55, 2013 [IF 1.8, CI 18]
101.

Takada N, Abe T, Shinohara N, Sazawa A, Maruyama S, Shinno Y, Sato S,

Mitsuhashi K, Sato T, Sugishita K, Kamota S, Yamashita T, Ishizaki J, Hioka T, Mouri G,
Ono T, Miyajima N, Sakuta T, Mochizuki T, Aoyagi T, Katano H, Akino T, Hirakawa K,
Minami K, Kumagai A, Seki T, Togashi M, Nonomura K: Perioperative Morbidity andMortality related to Radical Cystectomy－A Multi-institutional Retrospective Study inJapan. BJU Int. 2012 Dec;110(11 Pt B):E756-64. [IF 4.5, CI 20]
102.

Kunieda F, Kitamura H, Niwakawa M, Kuroiwa K, Shinohara N, Tobisu K,

Nakamura K, Shibata T, Tsuzuki T, Tsukamoto T, Kakehi Y, and Urological Oncology Study
Group of the Japn Clinical Oncology Group: Watchful waiting versus intravesical BCG
therapy for high-grade pT1 bladder cancer with pT0 histology in the second transurethralresection: Japan Clinical Oncology Group Study JCOG1019. Jpn. J. Clin. Oncol. 42(11),1094-1098, 2012 [IF 2.4, CI 6]
103.

Takeda N, Isu K, Hiraga H, Shinohara N, Minami A, Kamata H: Radiotherapy withzoledronic acid for bone metastases from renal cell carcinoma: More than a 24-month
median follow-up. J. Orthop. Sci. 17(6), 770-774, 2012 [IF 1.7, CI 6]
104.

Maru S, Ishigaki Y, Shinohara N, Takata T, Tomosugi N, Nonomura K: Efficacy ofATP-competitive inhibitors of mTORC2 on regulation of E-cadherin via HIF-2α in the renal
cell carcinoma cell line 786-O.
105.

J. Urol. 189(5), 1921-1929, 2013 [IF 6.6, CI 15]

Akiyama K, Ohga N, Maishi N, Hida Y, Kitayama K, Kawamoto T, Osawa T, Suzuki

Y, Shinohara N, Nonomura K, Shindoh M, Hida K.: The F-prostaglandin receptor is a novel
marker for tumor endothelial cells in renal cell carcinoma. Pathol. Int. 63(1), 37-44, 2013 [IF
2.2, CI 10]
106.

Naito S, Kinoshita H, Kondo T, Shinohara N, Kasahara T, Saito K, Takayama T,

Masumori N, Takahashi W, Takahashi M, Terachi T, Ozono S, Naito S, Tomita Y: Prognostic
Factors of Metastatic Renal Cell Carcinoma Patients with Removed Metastases: A
Multicentre Study of 559 Patients. Urology 82(4), 846-851, 2013 [IF 2.1, CI 20]
107.

Shinohara N, Maruyama S, Shimizu S, Nishioka K, Abe T, Hatanaka K, Oba K,

Nonomura K, Shirato H: Longitudinal comparison of quality of life after real-time tumortracking intensity-modulated radiation therapy and radical prostatectomy in patients withlocalized prostate cancer. J. Radiat. Res. 54(6), 1095-1101, 2013 [IF 2.0, CI 8]
108.

Osawa T, Shinohara N, Maruyama S, Oba K, Abe T, Maru S, Takada N, Sazawa A,

Nonomura K: Long-term renal function outcomes in bladder cancer after radical
cystectomy. Urol. J. 10(1), 784-789, 2013 [IF 1.5, CI 10]
109.

Ueda T, Uemura H, Tomita Y, Tsukamoto T, Kanayama H, Shinohara N, Tarazl J,

Chen C, Kim S, Ozono S, Naito S, Akaza H: Efficacy and safey of axitinib versus sorafenibin metastatic renal cell carcinoma: subgroup analysis of Japanese patients from a randomized
phase 3 AXIS trial. Jpn. J. Clin. Oncol. 43(6), 616-628, 2013 [IF 2.4, CI 42]

110.

Osawa T, Ohga N, Hida Y, Kitayama K, Akiyama K, Onodera Y, Fujita M,

Shinohara N, Nonomura K, Shindoh M, Hida K: Lysyl oxidase secreted by tumor
endothelial cells promotes angiogenesis and metastasis.

Br J Cancer 109(8), 2237-2247,

2013 [IF 8.8, CI 45]

111.

Shinohara N, Abe T, Mochizuki T, Kashiwagi A, Kanagawa K, Maruyama S, Sazawa

A, Oba K, Nonomura K: Is Memorial Sloan-Kettering Cancer Center risk classification
appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era ?
Urol. Oncol. 31(7), 1276-1282, 2013 [IF 2.7, CI 12]
112.

Miyajima N, Tsutsumi S, Sourbier C, Beebe K, Mollapour M, Rivas C, Yoshida S,

Trepel JB, Huang Y, Tatokoro M, Shinohara N, Nonomura K, Neckers L.: The HSP90
inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinibsensitive and crizotinib-resistant MET-driven tumor models. Cancer Res. 73(23), 7022-7033,
2013 [IF 11.2, CI 30]
113.

Hirono M, Kobayashi M, Tsushima T, Obara W, Shinohara N, Ito K, Eto M,

Takayama T, Fujii Y, Nishikido M, Kimura G, Kishida T, Takahashi M, Miyao N, Naya Y,
Abe T, Fujioka T, Ito K, Naito S.: Impacts of clinicopathologic and operative factors on
short-term and long-term survival in renal cell carcinoma with venous tumor thrombus
extension before introducing molecular-targeted therapy: a multi-institutional retrospective
study in Japan. BMC Cancer. 13, 447, 2013. doi: 10.1186/1471-2407-13-447 [IF 3.8, CI 18]
114.

Nishioka K, Shimizu S, Shinohara N, Ito YM, Abe T, Maruyama S, Kinoshita R,

Harada K, Nishikawa N, Miyamoto N, Onimaru R, Shirato H: Prospective Phase II study ofimage-guided local boost radiotherapy using a real-time tumor-tracking radiotherapy (RTRT)
system for locally advanced bladder cancer. Jpn J Clin Oncol. 2014 Jan;44(1):28-35. [IF 2.4,
CI 4]
115.

Shinohara N, Nonomura N, Eto M, Kimura G, Minami H, Tokunaga S, Naito S.

Arandomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing
ceramide with a low-friction external surface for hand-foot skinreaction caused by sorafenibin patients with renal cell carcinoma. Ann Oncol. 2014 Feb;25(2):472-6. [IF 50.5, CI 14]
116.

Abe T, Takada N, Shinohara N, Matsumoto R, Murai S, Sazawa A, Maruyama S

Tsuchiya K, Kanzaki S, Nonomura K: A comparison of 90-day complications between ileal
conduit and neobladder reconstruction after radical cystectomy－A retrospective multiinstitutional study in Japan. Int J Urol. 2014 Jun;21(6):554-9. [IF 2.6, CI 17]
117.

Abe T, Kitamura H, Tsukamoto T, Obara W, Fujioka T, Matsumura N, Hara I,

Shinohara N, Nonomura K: Outcome of metastasectomy for urothelial carcinoma: A multiinstitutional retrospective study. J Urol. 2014 Apr;191(4):932-6. [IF 6.6, CI 24]
118.

Naito S, Tatsugami K, Shinohara N, Tomita Y, Mizokami A, Fijisawa M, Hashine K,

NIshikido M, Nakagawa M, Tsukamoto T, Akaza H: Final results of phase II trial of S-1 inpatients with cytokine-refractory metastatic renal cell carcinoma.

Jpn J Clin Oncol. 2014

Feb;44(2):122-6. [IF 2.4, CI 1]
119.

Matsumoto R, Abe T, Shinohara N, Murai S, Maruyama S, Tsuchiya K, Nonomura K:

RENAL nephrometry score is a predictive factor for annual growth rate of renal mass. Int J
Urol. 2014 Jun;21(6):549-52. [IF 2.6, CI 4]
120.

Shimizu S, Nishioka K, Suzuki R, Shinohara N, Maruyama S, Abe T, Kinoshita R,

Katoh N, Onimaru R, Shirato H: Early results of urethral dose reduction and small safetymargin in intensity-modulated radiation therapy (IMRT) for localized prostate cancer using areal-time tumor-tracking radiotherapy (RTRT) system. Radiat Oncol. 2014 May 21;9:118.
[IF 3.6, CI 0]
121.

Otsubo T, Hida Y, Ohga N, Sato H, Kai T, Matsuki Y, Takasu H, Akiyama K, Maishi

N, Kawamoto T, Shinohara N, Nonomura K, Hida K.: Identification of novel targets forantiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial
cells. Cancer Sci. 2014 May;105(5):560-7. [IF 5.7, CI 18]
122.

Alam MT, Nagao-Kitamoto H, Ohga N, Akiyama K, Maishi N, Kawamoto T,

Shinohara N, Taketomi A, Shindoh M, Hida Y, Hida K. Suprabasin as a novel tumor
endothelial cell marker. Cancer Sci. 2014 Dec;105(12):1533-40. [IF 5.7, CI 18]
123.

Ara MN, Hyodo M, Ohga N, Akiyama K, Hida K, Hida Y, Shinohara N, Harashima

H.: Identification and expression of troponin T, a new marker on the surface of cultured
tumor endothelial cells by aptamer ligand. Cancer Med. 2014 Aug;3(4):825-34. [IF 4.0, CI
8]

124.

Eto M, Kawano Y, Hirao Y, Mita K, Arai Y, Tsukamoto T, Hashine K, Matsubara A,

Fujioka T, Kimura G, Shinohara N, Tatsugami K, Hinotsu S, Naito S; Japan RCC Trialist
Collaborative Group (JRTCG) investigators.: Phase II clinical trial of sorafenib plus
interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan. BMC
cancer 2015; 15(1):667
125.

[IF 3.8, CI 7]

Ohmura-Kakutani H, Akiyama K, Maishi N, Ohga N, Hida Y, Kawamoto T, Iida J,

Shindoh M, Tsuchiya K, Shinohara N, Hida K. Identification of tumor endothelial cells withhigh aldehyde dehydrogenase activity and a highly angiogenic phenotype. PLoS One. 2014
Dec 1;9(12):e113910. doi: 10.1371/journal.pone.0113910 [IF 3.7, CI 35]
126.

Abe T, Takada N, Matsumoto R, Osawa T, Sazawa A, Maruyama S, Tsuchiya K,

Harabayashi T, Minami K, Nagamori S, Hatanaka KC, Tanaka Y, Shinohara N, Nonomura
K. Outcome of regional lymphadenectomy in accordance with primary tumor location on
laparoscopic nephroureterectomy for urothelial carcinoma of the upper urinary tract: aprospective study. J Endourol. 2015 Mar;29(3):304-9. [IF 2.7, CI 10]
127.

Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I, Anai S, Harada H, Tsujikawa K,

Konishi N, Shinohara N, Nakajima Y. Clinical significance and therapeutic potential of
prostate cancer antigen-1/ALKBH3 in human renal cell carcinoma. Oncol Rep. 2015
Aug;34(2):648-54. [IF 4.2, CI 12]
128.

Kojima T, Kawai K, Tsuchiya K, Abe T, Shinohara N, Tanaka T, Masumori N,

Yamada S, Arai Y, Narita S, Tsuchiya N, Habuchi T, Nishiyama H. Identification of a
subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor. Int
J Urol. 2015 Oct;22(10):923-7. [IF 2.6, CI 8]
129.

Matsumoto R, Takada N, Abe T, Minami K, Harabayashi T, Nagamori S, Hatanaka

KC, Miyajima N, Tsuchiya K, Maruyama S, Murai S, Shinohara N. Prospective mapping oflymph node metastasis in Japanese patients undergoing radical cystectomy for bladdercancer: characteristics of micrometastasis. Jpn J Clin Oncol. 2015 Sep;45(9):874-80. [IF 2.4,
CI 3]
130.

Matsumoto R, Tsuda M, Wang L, Maishi N, Abe T, Kimura T, Tanino M, Nishihara H,

Hida K, Ohba Y, Shinohara N, Nonomura K, Tanaka S. Adaptor protein CRK inducesepithelial-mesenchymal transition and metastasis of bladder cancer cells through HGF/c-Met
feedback loop. Cancer Sci. 2015 Jun;106(6):709-717. [IF 5.7, CI 23]
131.

Mitsui T, Araki A, Miyashita C, Ito S, Ikeno T, Sasaki S, Kitta T, Moriya K, Cho K,

Morioka K, Kishi R, Shinohara N, Takeda M, Nonomura K. The Relationship between theSecond-to-Fourth Digit Ratio and Behavioral Sexual Dimorphism in School-Aged Children.
PLoS One. 2016 Jan 12;11(1):e0146849. [IF 3.7, CI 7]
132.

Moriya K, Mitsui T, Kitta T, Nakamura M, Kanno Y, Kon M, Nishimura Y, Shinohara

N, Nonomura K: Early Discontinuation of Antibiotic Prophylaxis in Patients with PersistentPrimary Vesicoureteral Reflux Initially Detected during Infancy: Outcome Analysis and Risk
Factors for Febrile Urinary Tract Infection. J Urol 2015, 193(2):637-642. [IF 6.6, CI 6]
133.

Naito S, Sakai H, Hashine K, Tomita Y, Shinohara N, Fujisawa M, Eto M, Ozono S,

Akaza H. Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell
carcinoma. Ann Oncol. 2015 Sep;26(9):1871-1876. [IF 50.5, CI 1]
134.

Shinohara N, Obara W, Tatsugami K, Naito S, Kamba T, Takahashi M, Murai S, Abe

T, Oba K, Naito S. Prognosis of Japanese patients with previously untreated metastatic renal
cell carcinoma in the era of molecular-targeted therapy. Cancer Sci. 2015 May;106(5):61826. [IF 5.7, CI 12]
135.

Tatsugami K, Shinohara N, Kondo T, Yamasaki T, Eto M, Tsushima T, Terachi T,

Naito S; Japanese Society of Renal Cancer. Role of cytoreductive nephrectomy for Japanesepatients with primary renal cell carcinoma in the cytokine and targeted therapy era. Int J
Urol. 2015 Aug;22(8):736-40. [IF 2.6, CI 8]
136.

Mitsui T, Kitta T, Moriya K, Takeda M, Shinohara N: Traumatic pediatric spinal cord

injury: long-term outcomes of lower urinary tract function. Spinal cord series and cases
2015, 1:15023. [IF 1.2, CI 0]
137.

Chiba H, Mitsui T, Kitta T, Ohmura Y, Moriya K, Kanno Y, Yoshioka M, Shinohara

N. The role of serotonergic mechanism in the rat prefrontal cortex for controlling themicturition reflex: An in vivo microdialysis study. Neurourol Urodyn. 2016 Nov;35(8):902907. [IF 2.0, CI 3]

138.

Yokomizo A, Kanimoto Y, Okamura T, Ozono S, Koga H, Iwamura M, Tanaka H,

Takahashi S, Tsushima T, Kanayama HO, Akaza H, Shinohara N, Mugiya S, Nomata K,
Nakamura T, Naito S. Randomized Controlled Study of the Efficacy, Safety and Quality ofLife with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive
Bladder Cancer. J Urol. 2016 Jan;195(1):41-6. [IF 6,6, CI 16]
139.

Harada T, Abe T, Kato F, Matsumoto R, Fujita H, Murai S, Miyajima N, Tsuchiya K,

Maruyama S, Kudo K, Shinohara N. Five-point Likert scaling on MRI predicts clinicallysignificant prostate carcinoma. BMC Urol. 2015 Sep 4;15:91. [IF 2.0, CI 16]
140.

Murahashi N, Abe T, Shinohara N, Murai S, Harabayashi T, Sazawa A, Maruyama S,

Tsuchiya K, Miyajima N, Hatanaka K, Nonomura K. Diagnostic outcome of ureteroscopy inurothelial carcinoma of the upper urinary tract: Incidence of later cancer detection and its
risk factors after the first examination. BMC Urol. 2015 Sep 4;15:92. [IF 2.0, CI 1]
141.

Sasaki H, Wada H, Baghdadi M, Tsuji H, Otsuka R, Morita K, Shinohara N, Seino K.

New Immunosuppressive Cell Therapy to Prolong Survival of Induced Pluripotent StemCell-Derived Allografts. Transplantation. 2015 Nov;99(11):2301-10. [IF 6.2, CI 11]
142.

Kitta T, Chancellor MB, de Groat WC, Shinohara N, Yoshimura N: Role of theanterior cingulate cortex in the control of micturition reflex in a rat model of Parkinson's
disease. J Urol. 2016; 195(5):1613-1620. [IF 6.6, CI 11]
143.

Mitsui T, Moriya K, Morita K, Iwami D, Kitta T, Kanno Y, Takeda M, Shinohara N:

Risk Factors for Lower Urinary Tract Dysfunction and Symptoms After Successful Renal
Transplantation. Ann Transplant. 2015; 20:757-763. [IF 1.1, CI 1]
144.

Abe T, Sazawa A, Harabayashi T, Oishi Y, Miyajima N, Tsuchiya K, Maruyama S,

Okada H, Shinohara N: Laparoscopic resection of paraaortic/paracaval neurogenic tumors:
surgical outcomes and technical tips. Surg Endosc. 2016; 30(10):4640-4645. [IF 3.1, CI 6]
145.

Mitsui T, Araki A, Miyashita C, Ito S, Ikeno T, Sasaki S, Kitta T, Moriya K, Cho K,

Morioka K, Kishi R, Shinohara N, Takeda M, Nonomura K: The Relationship between theSecond-to-Fourth Digit Ratio and Behavioral Sexual Dimorphism in School-Aged Children.
PloS one 2016, 11(1):e0146849. [IF 3.7, CI 7]

Moriya K, Nakamura M, Nishimura Y, Kitta T, Kanno Y, Chiba H, Kon M, Shinohara

146.

N: Factors affecting post-pubertal penile size in patients with hypospadias. World J Urol. 2016,34(9):1317-1321. [IF 3.4, CI 2]
147.

Kon M, Saito K, Mitsui T, Miyado M, Igarashi M, Moriya K, Nonomura K,

Shinohara N, Ogata T, Fukami M: Copy Number Variations of the Azoospermia Factor
Region and SRY Are Not Associated with the Risk of Hypospadias. Sex Dev. 2016,
10(1):12-15. [IF 2.3, CI 2]
148.

Kitta T, Mitsui T, Kanno Y, Chiba H, Moriya K, Yoshioka M, Shinohara N:

Differences in neurotransmitter systems of ventrolateral periaqueductal gray between themicturition reflex and nociceptive regulation: An in vivo microdialysis study. Int J Urol.
2016, 23(7):593-598. [IF 2.6, CI 3]
149.

Moriya K, Nakamura M, Nishimura Y, Kitta T, Kanno Y, Chiba H, Kon M, Shinohara

N: Long-term impact of unilateral hypo/dysplastic kidney in infants with primary
vesicoureteral reflux. J Pediatr Urol. 2016, pii: S1477-5131(16)00068-1. [IF 2.0, CI 0]150.

Itoh S, Araki A, Mitsui T, Miyashita C, Goudarzi H, Sasaki S, Cho K, Nakazawa H,

Iwasaki Y, Shinohara N, Nonomura K, Kishi R: Association of perfluoroalkyl substances
exposure in utero with reproductive hormone levels in cord blood in the Hokkaido Study on
Environment and Children's Health. Environ Int. 2016, 94:51-59. [IF 11.8, CI 33]
151.

Mitsui T, Araki A, Goudarzi H, Miyashita C, Ito S, Sasaki S, Kitta T, Moriya K, Cho

K, Morioka K, Kishi R, Shinohara N, Takeda M, Nonomura K: Effects of adrenal androgens
during the prenatal period on the second to fourth digit ratio in school-aged children.
Steroids 2016, 113:46-51. [IF 2.7, CI 0]
152.

Osawa T, Lee CT, Abe T, Takada N, Hafez KS, Montgomery JS, Weizer AZ,

Hollenbeck BK, Skolarus TA, Murai S, Shinohara N, Morgan TM: A Multi-Center
International Study Assessing the Impact of Differences in Baseline Characteristics andPerioperative Care Following Radical Cystectomy. Bladder Cancer 2016, 2(2):251-261. [IF
1.1, CI 7]
153.

Kitta T, Yabe I, Takahashi I, Matsushima M, Sasaki H, Shinohara N: Clinical efficacy

of istradefylline on lower urinary tract symptoms in Parkinson's disease. Int J Urol. 2016

Oct;23(10):893-894

154.

[IF 2.6, CI 7]

Abe T, Matsumoto R, Shinohara N. Role of surgical consolidation in metastatic

urothelial carcinoma. Curr Opin Urol. 2016 Nov;26(6):573-80. [IF 2.5, CI 6]
155.

Nakamura A, Iwami D, Miyoshi H, Morita K, Taguri M, Terauchi Y, Shinohara N,

Atsumi T: Impact of renal transplantation on glucose tolerance in Japanese recipients with
impaired glucose tolerance. Diabet Med. 2017 Apr;34(4):569-576. [IF 3.5, CI 0]
156.

Matsumoto R, Tsuda M, Yoshida K, Tanino M, Kimura T, Nishihara H, Abe T,

Shinohara N, Nonomura K, Tanaka S: Aldo-keto reductase 1C1 induced by interleukin1beta mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
Sci Rep 2016, 6:34625. [IF 4.6, CI 38]
157.

Hida K, Maishi N, Kawamoto T, Akiyama K, Ohga N, Hida Y, Yamada K, Hojo T,

Kikuchi H, Sato M, Torii C, Shinohara N, Shindoh M. Tumor endothelial cells express highpentraxin 3 levels. Pathol Int. 2016 Dec;66(12):687-694. [IF 2.2, CI 6]
158.

Araki A, Mitsui T, Goudarzi H, Nakajima T, Miyashita C, Itoh S, Sasaki S, Cho K,

Moriya K, Shinohara N, Nonomura K, Kishi R. Prenatal di(2-ethylhexyl) phthalate
exposure and disruption of adrenal androgens and glucocorticoids levels in cord blood: The
Hokkaido Study. Sci Total Environ. 2017 Mar1;581-582:297-304. [IF 9.8, CI 17]
159.

Iwami D, Hotta K, Sasaki H, Hirose T, Higuchi H, Takada Y, Shinohara N: Highly

Immunogenic DQB1 Mismatch Eplets Are Associated With Development of Chronic Active
Antibody-Mediated Rejection: A First Report From Japan. Transplant Proc 2017, 49(1):8487. [IF 0.9, CI 1]
160.

Mitsui T, Morita K, Iwami D, Kitta T, Kanno Y, Moriya K, Takeda M, Shinohara N:

Does the Age of Donor Kidneys Affect Nocturnal Polyuria in Patients With Successful RealTransplantation? Transplant Proc 2017, 49(1):65-67. [IF 0.9, CI 0]
161.

Tomita Y, Fukasawa S, Oya M, Uemura H, Shinohara N, Habuchi T, Rini BI, Chen Y,

Bair AH, Ozono S, Naito S, Akaza H. Key predictive factors for efficacy of axitinib in firstline metastatic renal cell carcinoma: subgroup analysis in Japanese patients from arandomized, double-blind phase II study. Jpn J Clin Oncol. 2016 Nov 1;46(11):1031-1041.

[IF 2.4, CI 12]
162.

Araki A, Miyashita C, Mitsui T, Goudarzi H, Mizutani F, Chisaki Y, Itoh S, Sasaki S,

Cho K, Moriya K, Shinohara N, Nonomura K, Kishi R. Prenatal organochlorine pesticide
exposure and the disruption of steroids and reproductive hormones in cord blood: The
Hokkaido study. Environ Int. 2018 Jan;110:1-13. [IF 11.8, CI 14]
163.

Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Kimura

G, Yonese J, Yao M, Motzer RJ, Uemura H, McHenry MB, Berghorn E, Ozono S.
Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis
from the CheckMate 025 study. Jpn J Clin Oncol. 2017 Jul 1;47(7):639-646. [IF 2.4, CI 32]
164.

Takayanagi S, Mukasa A, Nakatomi H, Kanno H, Kuratsu JI, Nishikawa R, Mishima

K, Natsume A, Wakabayashi T, Houkin K, Terasaka S, Yao M, Shinohara N, Shuin T, Saito
N. Development of Database and Genomic Medicine for von Hippel-Lindau Disease inJapan. Neurol Med Chir (Tokyo). 2017 Feb 15;57(2):59-65. [IF 1.9, CI 2]165.

Oya M, Tomita Y, Fukasawa S, Shinohara N, Habuchi T, Rini BI, Fujii Y, Kamei Y,

Umeyama Y, Bair AH, Uemura H. Overall survival of first-line axitinib in metastatic renal
cell carcinoma: Japanese subgroup analysis from phase II study. Cancer Sci. 2017
Jun;108(6):1231-1239. [IF 5.7, CI 9]
166.

Noguchi S, Shinohara N, Ito T, Ohtsu A, Ravaud A, Jerusalem G, Ohno N, Gallo J,

Bouillaud E, Fan J, Nonomura N. Relationship between Pulmonary Adverse Events andEverolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology
Trials. Oncology. 2017;92(5):243-254. [IF 3.5, CI 2]
167.

Nishioka K, Shimizu S, Shinohara N, Ito YM, Abe T, Maruyama S, Katoh N,

Kinoshita R, Hashimoto T, Miyamoto N, Onimaru R, Shirato H. Analysis of inter- and intra
fractional partial bladder wall movement using implanted fiducial markers. Radiat Oncol.
2017 Mar 1;12(1):44. [IF 3.6, CI 3]
168.

Nishimura Y, Moriya K, Nakamura M, Nishida M, Sato M, Kudo Y, Omotehara S,

Iwai T, Wakabayashi Y, Kanno Y, Kitta T, Kon M, Shinohara N. Prevalence andChronological Changes of Testicular Microlithiasis in Isolated Congenital Undescended
Testes Operated On at Less Than 3 Years of Age. Urology. 2017 Nov;109:159-164. [IF 2.1,

CI 2]
169.

Moriya K, Nakamura M, Nishimura Y, Kanno Y, Kitta T, Kon M, Shinohara N.

Prevalence of and risk factors for symptomatic urinary tract infection after endoscopic
incision for the treatment of ureterocele in children. BJU Int. 2017 Sep;120(3):409-415. [IF
4.5, CI 0]
170.

Minatoya M, Sasaki S, Araki A, Miyashita C, Itoh S, Yamamoto J, Matsumura T,

Mitsui T, Moriya K, Cho K, Morioka K, Minakami H, Shinohara N, Kishi R. Cord Blood
Bisphenol A Levels and Reproductive and Thyroid Hormone Levels of Neonates: The
Hokkaido Study on Environment and Children's Health. Epidemiology. 2017 Oct;28 Suppl
1:S3-S9. [IF 5.4, CI 16]
171.

Kitta T, Kanno Y, Chiba H, Moriya K, Maruyama S, Abe T, Shinohara N. Radical

prostatectomy restores detrusor contraction pattern according to pressure flow parameters.
Int J Urol. 2017 Apr;24(4):301-307.
172.

[IF 2.6, CI 2]

Hirose T, Tanaka Y, Tanaka A, Sakai H, Sasaki Y, Shinohara N, Ohdan H. PD-L1/PD-

L2-expressing B-1 cells inhibit alloreactive T cells in mice. PLoS One. 2017 Jun
1;12(6):e0178765. [IF 3.7, CI 11]
173.

Hida K, Maishi N, Akiyama K, Ohmura-Kakutani H, Torii C, Ohga N, Osawa T,

Kikuchi H, Morimoto H, Morimoto M, Shindoh M, Shinohara N, Hida Y. Tumor
endothelial cells with high aldehyde dehydrogenase activity show drug resistance. Cancer
Sci. 2017 Nov;108(11):2195-2203. [IF 5.7, CI 23]
174.

Hida K, Kawamoto T, Maishi N, Morimoto M, Akiyama K, Ohga N, Shindoh M,

Shinohara N, Hida Y. miR-145 promoted anoikis resistance in tumor endothelial cells. J
Biochem. 2017 Aug 1;162(2):81-84. [IF 2.7, CI 4]
175.

Hara T, Fujimoto H, Kondo T, Shinohara N, Obara W, Kimura G, Kume H,

Nonomura N, Hongo F, Sugiyama T, Kanayama HO, Takahashi M, Fukumori T, Eto M;
Cancer Registration Committee of the Japanese Urological Association. Active heavy
cigarette smoking is associated with poor survival in Japanese patients with advanced renal
cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese
Urological Association. Jpn J Clin Oncol. 2017 Dec 1;47(12):1162-1169. [IF 2.4, CI 3]

176.

Araki A, Mitsui T, Goudarzi H, Nakajima T, Miyashita C, Itoh S, Sasaki S, Cho K,

Moriya K, Shinohara N, Nonomura K, Kishi R. Prenatal di(2-ethylhexyl) phthalate
exposure and disruption of adrenal androgens and glucocorticoids levels in cord blood: The
Hokkaido Study. Sci Total Environ. 2017 Mar 1;581-582:297-304. [IF 9.8, CI 17]
177.

Abe T, Takada N, Kikuchi H, Matsumoto R, Osawa T, Murai S, Miyajima N,

Maruyama S, Shinohara N. Perioperative morbidity and mortality of octogenarians treatedby radical cystectomy-a multi-institutional retrospective study in Japan. Jpn J Clin Oncol.
2017 Aug 1;47(8):755-761. [IF 2.4, CI 2]
178.

Abe T, Ishizaki J, Kikuchi H, Minami K, Matsumoto R, Harabayashi T, Sazawa A,

Mochizuki T, Chiba S, Akino T, Murakumo M, Miyajima N, Tsuchiya K, Maruyama S,
Murai S, Shinohara N. Outcome of metastatic urothelial carcinoma treated by systemic
chemotherapy: Prognostic factors based on real-world clinical practice in Japan. Urol Oncol.
2017 Feb;35(2):38.e1-38.e8. [IF 2.7, CI 10]
179.

Takizawa A, Kawai K, Kawahara T, Kojima T, Maruyama S, Shinohara N, Akamatsu

S, Kamba T, Nakamura T, Ukimura O, Jikuya R, Kishida T, Kakimoto K, Nishimura K,
Harabayashi T, Nagamori S, Yamashita S, Arai Y, Sawada Y, Sekido N, Kinoshita H,
Matsuda T, Nakagawa T, Homma Y, Nishiyama H. The usefulness of testosterone
administration in identifying false-positive elevation of serum human chorionic gonadotropin
in patients with germ cell tumor. J Cancer Res Clin Oncol. 2018 Jan;144(1):109-115. [IF 3.6,
CI 2]
180.

Ouchi M, Kitta T, Kanno Y, Moriya K, Suzuki S, Shinohara N, Kato K. Medium-

term follow-up after supervised pelvic floor muscle training for patients with anterior vaginalwall prolapse. Eur J Obstet Gynecol Reprod Biol. 2018 Jun;225:95-100. [IF 2.6, CI 1]
181.

Ouchi M, Kitta T, Kanno Y, Higuchi M, Togo M, Moriya K, Shinohara N. Effect of a

5-HT2c receptor agonist on urethral closure mechanisms in female rats. Neurourol Urodyn.
2018 Nov;37(8):2382-2388. [IF 2.0, CI 0]
182.

Osawa T, Abe T, Takada N, Ito YM, Murai S, Shinohara N. Validation of thenomogram for predicting 90-day mortality after radical cystectomy in a Japanese cohort. Int
J Urol. 2018 Jul;25(7):699-700. [IF 2.6, CI 2]

183.

Nakano K, Iwami D, Yamada T, Morita K, Yasuda K, Shibuya H, Kahata K,

Shinohara N, Shimizu C. Development of a Formula to Correct Particle-Enhanced
Turbidimetric Inhibition Immunoassay Values so That it More Precisely Reflects HighPerformance Liquid Chromatography Values for Mycophenolic Acid. Transplant Direct.
2017 Dec 13;4(1):e337. [IF 2.3, CI 0]184.

Nakamura M, Moriya K, Nishimura Y, Nishida M, Kudo Y, Kanno Y, Kitta T, Kon M,

Shinohara N. Prevalence and risk factors of testicular microlithiasis in patients withhypospadias: a retrospective study. BMC Pediatr. 2018 May 29;18(1):179. [IF 2.4, CI 3]
185.

Moriya K, Nakamura M, Nishimura Y, Nishida M, Kudo Y, Kanno Y, Kitta T, Kon M,

Shinohara N. Impact of Preoperative Ultrasonographic Evaluation for Detection of a Viable
Testis in Patients With a Unilateral Nonpalpable Testis. J Ultrasound Med. 2018
Jul;37(7):1665-1670. [IF 2.3, CI 2]
186.

Miyashita C, Araki A, Mitsui T, Itoh S, Goudarzi H, Sasaki S, Kajiwara J, Hori T, Cho

K, Moriya K, Shinohara N, Nonomura K, Kishi R. Sex-related differences in theassociations between maternal dioxin-like compounds and reproductive and steroid
hormones in cord blood: The Hokkaido study. Environ Int. 2018 Aug;117:175-185.. [IF 11.8,
CI 4]
187.

Mitsui T, Araki A, Goudarzi H, Miyashita C, Ito S, Sasaki S, Kitta T, Moriya K, Cho

K, Morioka K, Kishi R, Shinohara N, Takeda M, Nonomura K. Relationship between
adrenal steroid hormones in cord blood and birth weight: The Sapporo Cohort, Hokkaido
Study on Environment and Children's Health. Am J Hum Biol. 2018 Jul;30(4):e23127. [IF
2.9, CI 2]
188.

Matsumoto R, Abe T, Ishizaki J, Kikuchi H, Harabayashi T, Minami K, Sazawa A,

Mochizuki T, Akino T, Murakumo M, Osawa T, Maruyama S, Murai S, Shinohara N.
Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving secondline chemotherapy: an analysis of real-world clinical practice data in Japan. Jpn J Clin
Oncol. 2018 Aug 1;48(8):771-776. [IF 2.4, CI 12]
189.

Kon M, Mitsui T, Kitta T, Moriya K, Shinohara N, Takeda M, Nonomura K. Impact

of posterior urethral diameter/external urethral sphincter diameter as a new tool to predictdetrusor pressure in the voiding phase. Int Urol Nephrol. 2018 Feb;50(2):211-215. [IF 2.0,
CI 0]
190.

Kitta T, Yabe I, Kanno Y, Higuchi M, Ouchi M, Togo M, Moriya K, Takahashi I,

Matsushima M, Sasaki H, Shinohara N. Long-term Outcome of Adenosine A2A Receptor
Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients. Clin
Neuropharmacol. 2018 May/Jun;41(3):98-102. [IF 1.0, CI 7]
191.

Kitta T, Kanno Y, Chiba H, Higuchi M, Ouchi M, Togo M, Moriya K, Shinohara N.

Benefits and limitations of animal models in partial bladder outlet obstruction fortranslational research. Int J Urol. 2018 Jan;25(1):36-44. [IF 2.6, CI 18]
192.

Iwami D, Aramaki O, Shinohara N, Niimi M, Shirasugi N. Administration of donor

splenocytes via the respiratory tract generates CD8α(+) regulatory dendritic cells andinduces hyporesponsiveness to fully allogeneic cardiac grafts. Transplant immunology.
2018;50:60-7. [IF 1.5, CI 0]193.

Ito K, Mikami S, Tatsugami K, Masumori N, Shinohara N, Kondo T, Nakanishi S,

Nagashima Y, Eto M, Kamba T, Kuroda N, Tomita Y, Matsuyama H, Onishi T, Tsushima T,
Nakazawa H, Oya M, Ozono S, Naito S, Asano T. Clinical Outcomes in Patients With
Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan. Clin
Genitourin Cancer. 2018 Dec;16(6):e1201-e1214.. [IF 3.2, CI 2]
194.

Hirose T, Hotta K, Iwami D, Harada H, Morita K, Tanabe T, Sasaki H, Fukuzawa N,

Seki T, Shinohara N. Safety and Efficacy of Retroperitoneoscopic Living Donor
Nephrectomy: Comparison of Early Complication, Donor and Recipient Outcome with
Hand-Assisted Laparoscopic Living Donor Nephrectomy. J Endourol. 2018
Dec;32(12):1120-1124.. [IF 2.7, CI 1]
195.

Araki A, Miyashita C, Mitsui T, Goudarzi H, Mizutani F, Chisaki Y, Itoh S, Sasaki S,

Cho K, Moriya K, Shinohara N, Nonomura K, Kishi R. Prenatal organochlorine pesticide
exposure and the disruption of steroids and reproductive hormones in cord blood: The
Hokkaido study. Environ Int. 2018 Jan;110:1-13.. [IF 11.8, CI 14]
196.

Abe T, Raison N, Shinohara N, Shamim Khan M, Ahmed K, Dasgupta P. The Effectof Visual-Spatial Ability on the Learning of Robot-Assisted Surgical Skills. Journal ofsurgical education. 2018;75(2):458-64. [IF 2.9, CI 6]
197.

Abe T, Kondo T, Harabayashi T, Takada N, Matsumoto R, Osawa T, Minami K,

Nagamori S, Maruyama S, Murai S, Tanabe K, Shinohara N. Comparative study of lymph
node dissection, and oncological outcomes of laparoscopic and open radical
nephroureterectomy for patients with urothelial carcinoma of the upper urinary tract
undergoing regional lymph node dissection. Jpn J Clin Oncol. 2018 Nov 1;48(11):10011011.. [IF 2.4, CI 11]
198.

Takahashi S, Kinuya S, Nonomura N, Shinohara N, Suzuki K, Suzuki H, Nakamura

K, Satoh T, Tateishi U, Yoneda T, Horikoshi H, Igawa T, Kamai T, Koizumi M, Kosaka T,
Matsubara N, Miyake H, Mizokami A, Mizowaki T, Nakamura N, Nozawa M, Takahashi T,
Uemura H, Uemura M, Yokomizo A, Yoshimura M, Kakehi Y.: Japanese Expert Panel
Meeting on the Management of Prostate Cancer with Bone Metastases. Oncol Ther. 2018
Dec;6(2):157-171. [IF 2.7, CI 1]
199.

Tomita Y, Uemura H, Oya M, Shinohara N, Habuchi T, Fujii Y, Kamei Y, Umeyama

Y, Bair AH, Rini BI. Patients with metastatic renal cell carcinoma who benefit from axitinib
dose titration: analysis from a randomised, double-blind phase II study. BMC Cancer. 2019
Jan 7;19(1):17.. [IF 3.8, CI 2]
200.

Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Saito M,

Kimura G, Yonese J, Yao M, Uemura H. Nivolumab versus everolimus in advanced renal
cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate
025 study. Jpn J Clin Oncol. 2019 Jun 1;49(6):506-514.. [IF 2.4, CI 28]
201.

Tanaka N, Yamamoto M, Abe T, Osawa T, Matsumoto R, Shinohara N, Saito H,

Uchida Y, Morimoto Y. Changes of Cerebral Blood Volume During Robot-Assisted
Laparoscopic Radical Prostatectomy: Observational Prospective Study Using Near- Infrared
Time-Resolved Spectroscopy. J Endourol. 2019 Dec;33(12):995-1001.. [IF 2.7, CI 8]
202.

Sekizaki T, Kameda H, Oba C, Yong Cho K, Nakamura A, Miyoshi H, Osawa T,

Shinohara N, Atsumi T. Nivolumab-induced hypophysitis causing secondary adrenal
insufficiency after transient ACTH elevation. Endocr J. 2019 Oct 28;66(10):937-941.. [IF
2.0, CI 7]

203.

Ouchi M, Kitta T, Suzuki S, Shinohara N, Kato K. Evaluating pelvic floor muscle

contractility using two-dimensional transperineal ultrasonography in patients with pelvic
organ prolapse. Neurourology and urodynamics. 2019;38(5):1363-9. [IF 2.0, CI 3]
204.

Ouchi M, Kitta T, Kanno Y, Higuchi M, Togo M, Takahashi Y, Moriya K, Shinohara

N. Dopaminergic urethral closure mechanisms in a rat model of Parkinson's disease.
Neurourol Urodyn. 2019 Jun;38(5):1203-1211.. [IF 2.0, CI 1]
205.

Osawa T, Wei JT, Abe T, Kako Y, Murai S, Shinohara N. Development of theJapanese version of the health-related quality of life questionnaire for bladder cancer patientsusing the Bladder Cancer Index: A pilot study. Int J Urol. 2019 Oct;26(10):1016-1017. [IF
2.6, CI 2]
206.

Nishimura Y, Moriya K, Kobayashi S, Araki A, Sata F, Mitsui T, Itoh S, Miyashita C,

Cho K, Kon M, Nakamura M, Kitta T, Murai S, Kishi R, Shinohara N. Association between
ESR1 polymorphisms and second to fourth digit ratio in school-aged children in the
Hokkaido Study. Steroids. 2019 Jan;141:55-62. [IF 2.7, CI 4]
207.

Moriya K, Nakamura M, Kon M, Nishimura Y, Kanno Y, Kitta T, Shinohara N. Risk

factors affecting post-pubertal high serum follicle-stimulating hormone in patients withhypospadias. World J Urol. 2019 Dec;37(12):2795-2799.. [IF 3.4, CI 1]
208.

Morii Y, Osawa T, Suzuki T, Shinohara N, Harabayashi T, Ishikawa T, Tanikawa T,

Yamashina H, Ogasawara K. Cost comparison between open radical cystectomy,
laparoscopic radical cystectomy, and robot-assisted radical cystectomy for patients withbladder cancer: a systematic review of segmental costs. BMC Urol. 2019 Nov 8;19(1):110..
[IF 2.0, CI 10]
209.

Mitsui T, Araki A, Miyashita C, Ito S, Ikeno T, Sasaki S, Kitta T, Moriya K, Cho K,

Morioka K, Kishi R, Shinohara N, Takeda M, Nonomura K. Effects of prenatal sex
hormones on behavioral sexual dimorphism. Pediatr Int. 2019 Feb;61(2):140-146.. [IF 1.4,
CI 4]
210.

Mikami S, Mizuno R, Kondo T, Shinohara N, Nonomura N, Ozono S, Eto M,

Tatsugami K, Takayama T, Matsuyama H, Kishida T, Oya M; Japanese Society of Renal
Cancer. Clinical significance of programmed death-1 and programmed death- ligand 1

expression in the tumor microenvironment of clear cell renal cell carcinoma. Cancer Sci.
2019 Jun;110(6):1820-1828.. [IF 5.7, CI 24]
211.

Maishi N, Kikuchi H, Sato M, Nagao-Kitamoto H, Annan DA, Baba S, Hojo T,

Yanagiya M, Ohba Y, Ishii G, Masutomi K, Shinohara N, Hida Y, Hida K. Development ofImmortalized Human Tumor Endothelial Cells from Renal Cancer. Int J Mol Sci. 2019 Sep
17;20(18):4595.. [IF 5.6, CI 7]
212.

Kume H, Homma Y, Shinohara N, Obara W, Kondo T, Kimura G, Fujimoto H,

Nonomura N, Hongo F, Sugiyama T, Takahashi M, Kanayama HO, Fukumori T, Eto M.
Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis
of a nation-wide registry program. Jpn J Clin Oncol. 2019 Aug 1;49(8):772-779.. [IF 2.4, CI
2]
213.

Kikuchi H, Abe T, Matsumoto R, Osawa T, Maruyama S, Murai S, Shinohara N.

Nephrometry score correlated with tumor proliferative activity inT1 clear cell renal cell
carcinoma. Urol Oncol. 2019 May;37(5):301.e19-301.e25.. [IF 2.7, CI 9]
214.

Iwami D, Hotta K, Sasaki H, Hirose T, Higuchi H, Takada Y, Iwahara N, Shinohara

N. A 2-mm Cutoff Value Is Reasonable and Feasible for Vascular Reconstruction in a Kidney
Allograft With Multiple Arteries. Transplant Proc. 2019 Jun;51(5):1317-1320.. [IF 0.9, CI 2]
215.

Harada K, Nozawa M, Uemura M, Tatsugami K, Osawa T, Yamana K, Kimura G,

Fujisawa M, Nonomura N, Eto M, Shinohara N, Tomita Y, Kondo Y, Ochi K, Anazawa Y,
Uemura H. Treatment patterns and outcomes in patients with unresectable or metastatic renal
cell carcinoma in Japan. Int J Urol. 2019 Feb;26(2):202-210.. [IF 2.6, CI 14]
216.

Dekura Y, Nishioka K, Hashimoto T, Miyamoto N, Suzuki R, Yoshimura T,

Matsumoto R, Osawa T, Abe T, Ito YM, Shinohara N, Shirato H, Shimizu S. The urethral
position may shift due to urethral catheter placement in the treatment planning for prostateradiation therapy. Radiat Oncol. 2019 Dec 12;14(1):226.. [IF 3.6, CI 9]
217.

Annan DA, Maishi N, Soga T, Dawood R, Li C, Kikuchi H, Hojo T, Morimoto M,

Kitamura T, Alam MT, Minowa K, Shinohara N, Nam JM, Hida Y, Hida K. Carbonic
anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in thetumor microenvironment. Cell Commun Signal. 2019 Dec 17;17(1):169.. [IF 8.4, CI 24]

218.

Abe T, Murai S, Nasuhara Y, Shinohara N. Characteristics of Medical Adverse

Events/Near Misses Associated With Laparoscopic/Thoracoscopic Surgery: A Retrospective
Study Based on the Japanese National Database of Medical Adverse Events. J Patient Saf.
2019 Dec;15(4):343-351.. [IF 2.2, CI 2]219.

Abe T, Dar F, Amnattrakul P, Aydin A, Raison N, Shinohara N, Khan MS, Ahmed K,

Dasgupta P. The effect of repeated full immersion simulation training in ureterorenoscopy on
mental workload of novice operators. BMC Med Educ. 2019 Aug 22;19(1):318.. [IF 3.6, CI
8]220.

Yokomizo A, Wakabayashi M, Satoh T, Hashine K, Inoue T, Fujimoto K, Egawa S,

Habuchi T, Kawashima K, Ishizuka O, Shinohara N, Sugimoto M, Yoshino Y, Nihei K,
Fukuda H, Tobisu KI, Kakehi Y, Naito S; JCOG0401 Investigators. Salvage Radiotherapy
Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy:
A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401)<sup>†</sup>. Eur Urol.
2020 Jun;77(6):689-698.. [IF 23.4, CI 6]
221.

Tomita Y, Naito S, Sassa N, Takahashi A, Kondo T, Koie T, Obara W, Kobayashi Y,

Teishima J, Takahashi M, Matsuyama H, Ueda T, Yamaguchi K, Kishida T, Shiroki R, Saika
T, Shinohara N, Oya M, Kanayama HO. Sunitinib Versus Sorafenib as Initial Targeted
Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial
CROSS-J-RCC. Clin Genitourin Cancer. 2020 Aug;18(4):e374-e385.. [IF 3.2, CI 6]
222.

Togo M, Kitta T, Kanno Y, Ouchi M, Tokiwa S, Huang T, Moriyama S, Nomura J,

Moriya K, Shinohara N. Lower urinary tract function improves after laparoscopic
sacrocolpopexy for elderly patients with pelvic organ prolapse. Low Urin Tract Symptoms.
2020 Sep;12(3):260-265.. [IF 1.3, CI 1]
223.

Takada Y, Kamimura D, Jiang JJ, Higuchi H, Iwami D, Hotta K, Tanaka Y, Ota M,

Higuchi M, Nishio S, Atsumi T, Shinohara N, Matsuno Y, Tsuji T, Tanabe T, Sasaki H,
Iwahara N, Murakami M. Increased urinary exosomal SYT17 levels in chronic active
antibody-mediated rejection after kidney transplantation via the IL-6 amplifier. Int Immunol.
2020 Sep 30;32(10):653-662..[IF 4.4, CI 11]
224.

Ouchi M, Kitta T, Takahashi Y, Chiba H, Higuchi M, Togo M, Shinohara N.

Reliability of manometry for assessing pelvic floor muscle function in healthy men.
Neurourol Urodyn. 2020 Jun;39(5):1464-1471.. [IF 2.0, CI 2]
225.

Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y,

Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe
N, Tamura K, Komiyama M, Goto T, Yokomizo A, Kohei N, Kashiwagi A, Murakami M,
Sazuka T, Yasumoto H, Iwamoto H, Mitsuzuka K, Morooka D, Shimazui T, Yamamoto Y,
Ikeshiro S, Nakagomi H, Morita K, Tomida R, Mochizuki T, Inoue T, Kitamura H, Yamada
S, Ito YM, Murai S, Nishiyama H, Shinohara N; Japanese Urological Oncology Group.
Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell
carcinoma. Cancer Sci. 2020 Jul;111(7):2460-2471.. [IF 5.7, CI 0]
226.

Nishimura Y, Moriya K, Kobayashi S, Araki A, Sata F, Mitsui T, Itoh S, Miyashita C,

Cho K, Kon M, Nakamura M, Kitta T, Murai S, Kishi R, Shinohara N. Association of
exposure to prenatal phthalate esters and bisphenol A and polymorphisms in the ESR1 genewith the second to fourth digit ratio in school- aged children: Data from the Hokkaido study.
Steroids. 2020 Jul;159:108637.. [IF 2.7, CI 6]
227.

Miyata H, Osawa T, Abe T, Kikuchi H, Matsumoto R, Maruyama S, Nishioka K,

Shimizu S, Hashimoto T, Shirato H, Shinohara N. The updated outcomes of bladderpreserving trimodal therapy using a real-time tumor-tracking radiotherapy system forpatients with muscle-invasive bladder cancer. Jpn J Clin Oncol. 2020 May 5;50(5):609-616..
[IF 2.4, CI 0]
228.

Mitsui T, Araki A, Miyashita C, Ito S, Kitta T, Moriya K, Shinohara N, Takeda M,

Kishi R; Japan Environment and Children’s Study Group*. Effect of the occupational
environment of parents on cryptorchidism. Pediatr Int. 2020 Nov;62(11):1256-1263.. [IF 1.4,
CI 1]
229.

Matsumoto R, Abe T, Takada N, Minami K, Harabayashi T, Nagamori S, Hatanaka

KC, Yamashiro K, Kikuchi H, Osawa T, Maruyama S, Shinohara N. Oncologic outcomes oflaparoscopic radical nephroureterectomy in conjunction with template-based lymph nodedissection: An extended follow-up study. Urol Oncol. 2020 Dec;38(12):933.e13-933.e18..
[IF 2.7, CI 3]
230.

Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa

O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y,
Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T,
Matsuyama H. Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese
Urological Association: Revision working position paper. Int J Urol. 2020 May;27(5):362368.. [IF 2.6, CI 7]
231.

Higuchi H, Kamimura D, Jiang JJ, Atsumi T, Iwami D, Hotta K, Harada H, Takada Y,

Kanno-Okada H, Hatanaka KC, Tanaka Y, Shinohara N, Murakami M. Orosomucoid 1 isinvolved in the development of chronic allograft rejection after kidney transplantation. Int
Immunol. 2020 May 8;32(5):335-346. [IF 4.4, CI 10]
232.

Chiba H, Kitta T, Ohmura Y, Higuchi M, Kon M, Nakamura M, Yoshioka M,

Shinohara N. Serotonin in the rat prefrontal cortex controls the micturition reflex through 5hydroxytryptamine 2A and 5-hydroxytryptamine 7 receptors. Int J Urol. 2020
Aug;27(8):684-689.. [IF 2.6, CI 3]233.

Abe T, Minami K, Harabayashi T, Sazawa A, Chiba H, Kikuchi H, Miyata H, Frumido

J, Matsumoto R, Osawa T, Junji I, Tango M, Satoshi C, Tomoshige A, Masashi M, Naoto M,
Kunihiko T, Satoru M, Murai S, Shinohara N. Prognostic impact of local radiotherapy on
metastatic urothelial carcinoma patients receiving systemic chemotherapy. Jpn J Clin Oncol.
2020 Feb 17;50(2):206-213.. [IF 2.4, CI 6]
234.

Kikuchi H, Maishi N, Annan DA, Alam MT, Dawood RIH, Sato M, Morimoto M,

Takeda R, Ishizuka K, Matsumoto R, Akino T, Tsuchiya K, Abe T, Osawa T, Miyajima N,
Maruyama S, Harabayashi T, Azuma M, Yamashiro K, Ameda K, Kashiwagi A, Matsuno Y,
Hida Y, Shinohara N, Hida K. Chemotherapy-Induced IL8 Upregulates MDR1/ABCB1 in
Tumor Blood Vessels and Results in Unfavorable Outcome. Cancer Res. 2020 Jul
15;80(14):2996-3008.. [IF 11.2, CI 13]
235.

Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa

O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y,
Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T,
Matsuyama H. Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese
Urological Association: Summary of the revision. Int J Urol. 2020 Sep;27(9):702-709.. [IF
2.6, CI 23]

236.

Kitta T, Chiba H, Kanno Y, Hattori T, Higuchi M, Ouchi M, Togo M, Takahashi Y,

Michishita M, Kitano T, Shinohara N. Bladder outlet obstruction disrupts circadian bladderfunction in mice. Sci Rep. 2020 Jul 14;10(1):11578. [IF 4.6, CI 2]
237.

Higuchi M, Abe T, Hotta K, Morita K, Miyata H, Furumido J, Iwahara N, Kon M,

Osawa T, Matsumoto R, Kikuchi H, Kurashima Y, Murai S, Aydin A, Raison N, Ahmed K,
Khan MS, Dasgupta P, Shinohara N. Development and validation of a porcine organ modelfor training in essential laparoscopic surgical skills. Int J Urol. 2020 Oct;27(10):929-938. [IF
2.6, CI 4]
238.

Tohi Y, Kato T, Matsumoto R, Shinohara N, Shiga K, Yokomizo A, Nakamura M,

Kume H, Mitsuzuka K, Sasaki H, Egawa S, Matsumura M, Hashine K, Inokuchi J, Eto M,
Baba H, Ichikawa T, Kinoshita H, Matsuda T, Kakehi Y, Sugimoto M. The impact ofcomplications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Resultsfrom the Prostate Cancer Research International: Active Surveillance JAPAN study. Int J
Clin Oncol. 2020 Dec;25(12):2107-2114 [IF 3.3, CI 4]
239.

Osawa T, Wei JT, Abe T, Honda M, Yamada S, Furumido J, Kikuchi H, Matsumoto R,

Hirakawa K, Sato Y, Sasaki Y, Harabayashi T, Takada N, Minami K, Tanaka H, Morita K,
Kashiwagi A, Miyajima N, Akino T, Murai S, Ito YM, Fukuhara S, Ogasawara K,
Shinohara N. Health-related quality of life in Japanese patients with bladder cancer
measured by a newly developed Japanese version of the Bladder Cancer Index. Int J Clin
Oncol. 2020 Dec;25(12):2090-2098. [IF 3.3, CI 2]
240.

Ebina K, Abe T, Higuchi M, Furumido J, Iwahara N, Kon M, Hotta K, Komizunai S,

Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X,
Konno A, Shinohara N. Motion analysis for better understanding of psychomotor skills inlaparoscopy: objective assessment-based simulation training using animal organs. Surg
Endosc. 2021 Aug;35(8):4399-4416. [IF 3.1, CI 9]
241.

Kitta T, Chiba H, Kanno-Kakibuchi Y, Hattori T, Higuchi M, Ouchi M, Togo M, Abe-

Takahashi Y, Michishita M, Kitano T, Shinohara N. Long-term administration of alpha-1
blocker can reverse the micturition pattern in a bladder outlet obstruction murine model. Int J
Urol. 2020 Dec;27(12):1150-1156. [IF 2.6, CI 0]242.

Yoshinaga K, Abe T, Okamoto S, Uchiyama Y, Manabe O, Ito YM, Tamura N, Ito N,

Yoshioka N, Washino K, Shinohara N, Tamaki N, Shiga T. Effects of Repeated 131I-MetaIodobenzylguanidine Radiotherapy on Tumor Size and Tumor Metabolic Activity in Patientswith Metastatic Neuroendocrine Tumors. J Nucl Med. 2021 May 10;62(5):685-694. [IF 9.3,
CI 1]
243.

Ito K, Mikami S, Kuroda N, Nagashima Y, Tatsugami K, Masumori N, Kondo T,

Takagi T, Nakanishi S, Eto M, Kamba T, Tomita Y, Matsuyama H, Tsushima T, Nakazawa H,
Oya M, Kimura G, Shinohara N, Asano T. Difficulty in differential diagnosis for renal
cancer with microscopic papillary architecture: overlapped pathological features among
papillary renal cell carcinoma (RCC), mutinous tubular and spindle cell carcinoma, andunclassified RCC. Lessons from a Japanese multicenter study Jpn J Clin Oncol. 2020 Oct
22;50(11):1313-1320. [IF 2.4, CI 0]
244.

Yamashita S, Suzukamo Y, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura

T, Goto T, Osawa T, Yamada S, Nishimura K, Nonomura N, Nishiyama H, Shiraishi T,
Ukimura O, Ogawa O, Shinohara N, Ito A, Arai Y. Validation study of the Japanese versionof the European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire-Testicular Cancer 26 for patients with testicular cancer. Int J Urol. 2021
Feb;28(2):176-182. [IF 2.6, CI 2]
245.

Abe-Takahashi Y, Kitta T, Ouchi M, Okayauchi M, Chiba H, Higuchi M, Togo M,

Shinohara N. Reliability and validity of pelvic floor muscle strength assessment using the
MizCure perineometer. BMC Womens Health. 2020 Nov 19;20(1):257. [IF 2.5, CI 2]
246.

Kitta T, Hattori T, Chiba H, Higuchi M, Kanno-Kakibuchi Y, Ouchi M, Togo M, Abe-

Takahashi Y, Michishita M, Kitano T, Kusakabe N, Shinohara N. Are sham- operated mice a
valid comparator in studies using a bladder outlet obstruction model? A pitfall reveals ameaningful insight. Int J Urol. 2021 Mar;28(3):346-352. [IF 2.6, CI 0]247.

Nakai Y, Takeuchi A, Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Minami K,

Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Kashiwagi A, Murakami M, Sazuka T,
Yasumoto H, Morizane S, Kawasaki Y, Morooka D, Shimazui T, Yamamoto Y, Nakagomi H,
Tomida R, Ito YM, Murai S, Kitamura H, Nishiyama H, Shinohara N; Japanese Urological
Oncology Group. Efficacy and safety of second-line axitinib in octogenarians with metastatic
renal cell carcinoma. J Geriatr Oncol. 2021 Jun;12(5):834-837. [IF 3.0, CI 0]248.

Nakamura M, Moriya K, Kon M, Nishimura Y, Chiba H, Kitta T, Shinohara N. Girlsand renal scarring as risk factors for febrile urinary tract infection after stopping antibiotic
prophylaxis in children with vesicoureteral reflux. World J Urol. 2021 Jul;39(7):2587-2595.
[IF 3.4, CI 2]
249.

Tamura K, Osawa T, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M,

Sugimoto M, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Komiyama M, Tanaka K,
Yokomizo A, Kohei N, Shinohara N, Miyake H; Japanese Urological Oncology Group.
External validation of the albumin, C-reactive protein and lactate dehydrogenase model inpatients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a
Japanese multi-center cohort. Jpn J Clin Oncol. 2021 Apr 30;51(5):810-818. [IF 2.4, CI 0]250.

Abe-Takahashi Y, Kitta T, Ouchi M, Chiba H, Higuchi M, Togo M, Shinohara N.

Examination of pelvic floor muscle elasticity in patients with interstitial cystitis/bladder pain
syndrome using real-time tissue elastography. Int Urogynecol J. 2022 Mar;33(3):619-626.
[IF 1.8, CI 0]
251.

Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T,

Osawa T, Yamada S, Nishimura K, Nonomura N, Nishiyama H, Shiraishi T, Ukimura O,
Ogawa O, Shinohara N, Suzukamo Y, Ito A, Arai Y. Health-Related Quality of Life inTesticular Cancer Survivors in Japan: A Multi-Institutional, Cross-Sectional Study Using the
EORTC QLQ-TC26. Urology. 2021 Oct;156:173-180. [IF 2.1, CI 2]
252.

Tanabe T, Hotta K, Iwahara N, Iwami D, Murai S, Shinohara N. Spontaneous closureof arteriovenous fistula after kidney transplantation. Int J Urol. 2021 Aug;28(8):872-873. [IF
2.6, CI 0]253.

Miyake M, Nishimura N, Iida K, Fujii T, Nishikawa R, Teraoka S, Takenaka A,

Kikuchi H, Abe T, Shinohara N, Okajima E, Shimizu T, Hori S, Tsuchiya N, Owari T,
Murakami Y, Taoka R, Kobayashi T, Kojima T, Nishiyama N, Kitamura H, Nishiyama H,
Fujimoto K. Intravesical Bacillus Calmette-Guérin Treatment for T1 High-Grade NonMuscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies.
Cancers (Basel). 2021 May 26;13(11):2615. [IF 5.2, CI 4]

254.

Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T,

Osawa T, Yamada S, Nishimura K, Nonomura N, Kojo K, Shiraishi T, Ukimura O, Ogawa O,
Shinohara N, Suzukamo Y, Ito A, Arai Y. Fertility and reproductive technology use intesticular cancer survivors in Japan: A multi-institutional, cross-sectional study. Int J Urol.
2021 Oct;28(10):1047-1052. [IF 2.6, CI 4]
255.

Uemura M, Nakaigawa N, Sassa N, Tatsugami K, Harada K, Yamasaki T, Matsubara

N, Yoshimoto T, Nakagawa Y, Fukuyama T, Oya M, Shinohara N, Uemura H, Tsuzuki T.
Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell
carcinoma. Int J Clin Oncol. 2021 Nov;26(11):2073-2084. [IF 3.3, CI 2]
256.

Togo M, Kitta T, Chiba H, Ouchi M, Abe-Takahashi Y, Higuchi M, Kusakabe N,

Shinohara N. Can ultrasound measurement of bladder wall thickness be a useful adjunct for
regular urodynamics in children with spina bifida? J Pediatr Urol. 2021 Oct;17(5):734.e1734.e8. [IF 2.0, CI 0]
257.

Miyata H, Hirohashi Y, Yamada S, Yanagawa J, Murai A, Hashimoto S, Tokita S, Hori

K, Abe T, Kubo T, Tsukahara T, Kanaseki T, Shinohara N, Torigoe T. GRIK2 is a target for
bladder cancer stem-like cell-targeting immunotherapy. Cancer Immunol Immunother. 2022
Apr;71(4):795-806. [IF 5.8, CI 3]
258.

Kobayashi S, Sata F, Ikeda-Araki A, Miyashita C, Itoh S, Goudarzi H, Iwasaki Y,

Mitsui T, Moriya K, Shinohara N, Cho K, Kishi R. Associations among maternal
perfluoroalkyl substance levels, fetal sex-hormone enzymatic gene polymorphisms, and fetal
sex hormone levels in the Hokkaido study. Reprod Toxicol. 2021 Oct;105:221-231. [IF 3.3,
CI 1]
259.

Kikuchi H, Osawa T, Matsumoto R, Abe T, Maruyama S, Harabayashi T, Miyata H,

Kashiwagi A, Ikeshiro S, Sazawa A, Fukui R, Morita K, Takeuchi I, Hori K, Yamashita N,
Minami K, Mochizuki T, Murai S, Shinohara N. Efficacy of nivolumab plus ipilimumab asfirst-line therapy for primary tumors in patients with renal cell carcinoma. Urol Oncol. 2022
Jan;40(1):13.e19-13.e27. [IF 2.7, CI 0]
260.

Yamada S, Abe T, Sazawa A, Katano H, Suzuki H, Takeuchi I, Ishizaki J, Minami K,

Morita K, Tsuchiya K, Takada N, Maru S, Ishikawa S, Sato S, Kawazu T, Yamashita T, Ono
T, Mochizuki T, Akino T, Sasaki Y, Shinno Y, Furumido J, Miyata H, Kikuchi H, Matsumoto

R, Osawa T, Shinohara N. Comparative study of postoperative complications after radical
cystectomy during the past two decades in Japan: Radical cystectomy remains associatedwith significant postoperative morbidities. Urol Oncol. 2022 Jan;40(1):11.e17-11.e25. [IF
2.7, CI 2]
261.

Kon M, Nakamura M, Moriya K, Nishimura Y, Hirata Y, Nishida M, Higuchi M, Kitta

T, Shinohara N. What are the Optimal Renal Ultrasound Parameters for Detecting Small
Kidney in Young Children? Res Rep Urol. 2021 Oct 27;13:767-772. [IF 1.6, CI 1]
262.

Nishioka K, Gotoh K, Hashimoto T, Abe T, Osawa T, Matsumoto R, Yokota I, Katoh

N, Kinoshita R, Yasuda K, Yakabe T, Yoshimura T, Takao S, Shinohara N, Aoyama H,
Shimizu S, Shirato H. Are simple verbal instructions sufficient to ensure that bladder volume
does not deteriorate prostate position reproducibility during spot scanning proton therapy?
BJR Open. 2021 Nov 11;3(1):20210064. [IF NA, CI 0]263.

Aydın A, Ahmed K, Abe T, Raison N, Van Hemelrijck M, Garmo H, Ahmed HU,

Mukhtar F, Al-Jabir A, Brunckhorst O, Shinohara N, Zhu W, Zeng G, Sfakianos JP, Gupta
M, Tewari A, Gözen AS, Rassweiler J, Skolarikos A, Kunit T, Knoll T, Moltzahn F,
Thalmann GN, Lantz Powers AG, Chew BH, Sarica K, Shamim Khan M, Dasgupta P;
SIMULATE Trial Group. Effect of Simulation-based Training on Surgical Proficiency andPatient Outcomes: A Randomised Controlled Clinical and Educational Trial. Eur Urol. 2022
Apr;81(4):385-393. [IF 23.4, CI 13]
264.

Kikuchi H, Abe T, Matsumoto R, Osawa T, Maruyama S, Murai S, Shinohara N.

Outcomes of bacillus Calmette-Guérin therapy without a maintenance schedule for high-risk
non-muscle-invasive bladder cancer in the second transurethral resection era. Int J Urol.
2022 Mar;29(3):251-258. [IF 2.6, CI 1]
265.

Nakajima N, Miyajima A, Shinohara N, Obara W, Kondo T, Kimura G, Kume H,

Fujimoto H, Sugiyama T, Nonomura N, Hongo F, Fukumori T, Takahashi M, Kanayama HO,
Eto M. Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma:
sub-analysis of the multi-institutional national database of the Japanese Urological
Association. Jpn J Clin Oncol. 2022 Mar 3;52(3):274-280. [IF 2.4, CI 0]
266.

Harada M, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T,

Tozawa A, Sugimoto K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T,

Okada H, Kawai K, Shinohara N, Nagao K, Kitajima M, Suenobu S, Soejima T, Miyachi
M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N, Kanda Y, Fujii N, Endo M, Nakayama
R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M, Kikuchi I, Morishige KI,
Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, Sugiyama K, Boku N, Yonemura
M, Hayashi N, Aoki D, Osuga Y, Suzuki N. Japan Society of Clinical Oncology Clinical
Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adultcancer patients: part 1. Int J Clin Oncol. 2022 Feb;27(2):265-280. [IF 3.3, CI 6]
267.

Harada M, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T,

Tozawa A, Sugimoto K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T,
Okada H, Kawai K, Shinohara N, Nagao K, Kitajima M, Suenobu S, Soejima T, Miyachi
M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N, Kanda Y, Fujii N, Endo M, Nakayama
R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M, Kikuchi I, Morishige KI,
Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, Sugiyama K, Boku N, Yonemura
M, Hayashi N, Aoki D, Osuga Y, Suzuki N. Japan Society of Clinical Oncology Clinical
Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adultcancer patients: part 1. Int J Clin Oncol. 2022 Feb;27(2):265-280. [IF 3.3, CI 7]
268.

Nishimura Y, Moriya K, Kobayashi S, Ikeda-Araki A, Sata F, Mitsui T, Itoh S,

Miyashita C, Cho K, Kon M, Nakamura M, Kitta T, Murai S, Kishi R, Shinohara N.
Association of exposure to prenatal perﬂuoroalkyl substances and estrogen receptor 1
polymorphisms with the second to fourth digit ratio in school-aged children: The Hokkaido
study. Reprod Toxicol. 2022 Apr;109:10-18. [IF 3.3, CI 0]269.

Osawa T, Abe T, Kikuchi H, Matsumoto R, Murai S, Nakao T, Tanaka S, Watanabe,

Shinohara N. Validation of an online application to identify potential immune-related
adverse events associated with immune checkpoint inhibitors based on the patient's
symptoms. PLoS One. 2022 Mar 15;17(3):e0265230. [IF 3.7, CI 0]
270.

Ouchi M, Kitta T, Chiba H, Higuchi M, Togo M, Abe-Takahashi Y, Shinohara N.

Mechanisms of D1/D2-like dopaminergic agonist, rotigotine, on lower urinary tract function
in rat model of Parkinson's disease. Sci Rep. 2022 Mar 16;12(1):4540.. [IF 4.6, CI 0]
271.

Hirose T, Hotta K, Harada H, Tanabe T, Sasaki H, Shinohara N. Vesicoureteral reflux

treatment following kidney transplantation potentially prevents graft function deterioration
and allows long-term graft survival. Int J Urol. 2022 Jul;29(7):699-706. [IF 2.6, CI 0]272.

Chiba H, Kitta T, Higuchi M, Kusakabe N, Kon M, Nakamura M, Shinohara N.

Ureteral reimplantation during augmentation cystoplasty is not needed for vesicoureteral
reflux in patients with neurogenic bladder: a long-term retrospective study. BMC Urol. 2022
Mar 29;22(1):48. [IF 2.0, CI 2]
273.

Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K,

Shibuya S, Lingbo Y, Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai
S, Tsujita T, Sase K, Chen X, Konno A, Shinohara N. Objective evaluation of laparoscopic
surgical skills in wet lab training based on motion analysis and machine learning.
Langenbecks Arch Surg. 2022 Aug;407(5):2123-2132. [IF 2.3, CI 2]
274.

Uemura H, Tomita Y, Nonomura N, Yoshizaki K, Nakao T, Shinohara N. Real-world

safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a postmarketing surveillance. Int J Clin Oncol. 2022 Jun;27(6):1061-1067. [IF 3.3, CI 0]
275.

Kawahara T, Kawai K, Kojima T, Nagumo Y, Sakka S, Kandori S, Negoro H, Mathis

BJ, Maruo K, Miura K, Sakamoto N, Shinohara N, Yamashita S, Yonemori K, Kishida T,
Ukimura O, Nishimura K, Kobayashi Y, Nishiyama H. Phase II trial of nivolumab
monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors.
Int J Urol. 2022 Jul;29(7):741-747. [IF 2.6, CI 1]
276.

Kitta T, Abe H, Ting-Wen H, Fujikawa M, Nakazono M, Sasa T, Doi Y, Toki S, Okada

D, Ochi A, Suzuki K, Kitagawa Y, Shinohara N. Novel insight into the correlation between
hernia orifice of cystocele and lower urinary tract function: a pilot study. BMC Womens
Health. 2022 May 13;22(1):164. [IF 2.5, CI 0]
277.

Hirata Y, Higuchi M, Osawa T, Hinotsu S, Harabayashi T, Mochizuki T, Enami N,

Nounaka O, Shinno Y, Kikuchi H, Matsumoto R, Abe T, Murai S, Shinohara N. Late
recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free
periods. Int J Urol. 2022 Oct;29(10):1140-1146. [IF 2.6, CI 0]
278.

Nishioka K, Gotoh K, Hashimoto T, Abe T, Osawa T, Matsumoto R, Yokota I, Katoh

N, Kinoshita R, Yasuda K, Yakabe T, Yoshimura T, Takao S, Shinohara N, Aoyama H,
Shimizu S, Shirato H. Are simple verbal instructions sufficient to ensure that bladder volume

does not deteriorate prostate position reproducibility during spot scanning proton therapy?
BJR Open. 2021 Nov 11;3(1):20210064. [IF NA, CI 0]279.

Abe-Takahashi Y, Kitta T, Ouchi M, Chiba H, Higuchi M, Togo M, Shinohara N.

Evaluation of pelvic floor muscle elasticity in patients with overactive bladder syndrome
using real-time tissue elastography. Eur J Obstet Gynecol Reprod Biol. 2022 Sep;276:9-13.
[IF 2.6, CI 0]
280.

Yamamoto S, Noguchi H, Takeda A, Arakaki R, Uchishiba M, Imaizumi J, Minato S,

Kamada S, Kagawa T, Yoshida A, Kawakita T, Yamamoto Y, Yoshida K, Kon M, Shinohara
N, Iwasa T. Changes in Endogenous Oxytocin Levels and the Effects of Exogenous Oxytocin
Administration on Body Weight Changes and Food Intake in Polycystic Ovary Syndrome
Model Rats. Int J Mol Sci. 2022 Jul 26;23(15):8207. [IF 5.6, CI 3]
281.

Kitta T, Chiba H, Kon M, Higuchi M, Kusakabe N, Ouchi M, Togo M, Abe- Takahashi

Y, Tsukiyama M, Shinohara N. Urodynamic evaluation of the efficacy of vibegron, a new
β3-adrenergic receptor agonist, on lower urinary tract function in children and adolescentswith overactive bladder. J Pediatr Urol. 2022 Oct;18(5):563-569. [IF 2.0, CI 0]
282.

Yamada R, Morikawa K, Hotta K, Iwami D, Tanabe T, Murai S, Shinohara N,

Yoshida S, Hosoda S, Kubo A, Tokuchi Y, Kitagataya T, Kimura M, Yamamoto K, Nakai M,
Sho T, Suda G, Natsuizaka M, Ogawa K, Sakamoto N. Incidence of post- transplant hepatitis
B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus
infection. J Viral Hepat. 2022 Nov;29(11):976-985. [IF 2.5, CI 1]
283.

Nezu K, Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T,

Goto T, Osawa T, Nishimura K, Nonomura N, Negoro H, Shiraishi T, Ukimura O, Ogawa O,
Shinohara N, Suzukamo Y, Ito A, Arai Y. Association of financial toxicity with quality oflife in testicular cancer survivors. Int J Urol. 2022 Dec;29(12):1526-1534. [IF 2.6, CI 0]
284.

Furumido J, Maishi N, Yanagawa-Matsuda A, Kikuchi H, Matsumoto R, Osawa T,

Abe T, Matsuno Y, Shinohara N, Hida Y, Hida K. Stroma biglycan expression can be a
prognostic factor in prostate cancers. Int J Urol. 2023 Feb;30(2):147-154. [IF 2.6, CI 1]
285.

Kikuchi H, Osawa T, Abe T, Matsumoto R, Maruyama S, Murai S, Shinohara N.

Quality improvement in managing patients with non-muscle-invasive bladder cancer byintroducing a surgical checklist for transurethral resection of bladder tumor. PLoS One. 2022
Oct 27;17(10):e0276816. [IF 3.7, CI 0]
286.

Takenaka J, Watanabe S, Abe T, Hirata K, Uchiyama Y, Kimura R, Shinohara N,

Kudo K. Prognostic value of [18F]FDG-PET prior to [131I]MIBG treatment forpheochromocytoma and paraganglioma (PPGL). Ann Nucl Med. 2023 Jan;37(1):10-1. [IF
2.6, CI 2]
287.

Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K,

Shibuya S, Lingbo Y, Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai
S, Tsujita T, Sase K, Chen X, Konno A, Shinohara N. Automatic assessment of laparoscopic
surgical skill competence based on motion metrics. PLoS One. 2022 Nov
2;17(11):e0277105. [IF 3.7, CI 0]
288.

Iwasa T, Noguchi H, Aoki H, Tamura K, Maeda T, Takeda A, Uchishiba M, Arakaki R,

Minato S, Kamada S, Yamamoto S, Imaizumi J, Kagawa T, Yoshida A, Fukui R, Daizumoto
K, Kon M, Shinohara N, Yoshida K, Yamamoto Y. Effects of undernutrition and low energy
availability on reproductive functions and their underlying neuroendocrine mechanisms.
Endocr J. 2022 Dec 28;69(12):1363-1372. [IF 2.0, CI 2]
289.

Sato M, Osawa T, Abe T, Honda M, Higuchi M, Yamada S, Furumido J, Kikuchi H,

Matsumoto R, Sato Y, Sasaki Y, Harabayashi T, Maruyama S, Takada N, Minami K, Tanaka
H, Morita K, Kashiwagi A, Murai S, Ito YM, Ogasawara K, Shinohara N. Validation of theJapanese version of the Body Image Scale for bladder cancer patients. Sci Rep. 2022 Dec
13;12(1):21544. [IF 4.6, CI 0]
290.

Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y,

Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K,
Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N. IMAGENE
trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of
combination therapy of niraparib with PD-1 inhibitor in solid cancer patients withhomologous recombination repair genes mutation. BMC Cancer. 2022 Dec 9;22(1):1292. [IF
3.8, CI 0]
291.

Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H,

Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu

S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K,
Tanegashima T, Tokunaga S, Eto M; SNiP-RCC investigators. Effect of genetic
polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the
SNiP-RCC trial. Cancer Immunol Immunother. 2023 Jun;72(6):1903-1915. [IF 5.8, CI 1]
292.

Sakka S, Kandori S, Kawai K, Kojima T, Nitta S, Chihara I, Nagumo Y, Kawahara T,

Mathis BJ, Ishihara M, Shinohara N, Kishida T, Ukimura O, Nishimura K, Kobayashi Y,
Nishiyama H. Plasma circulating tumor DNA profiling in patients with chemo-refractory
germ cell tumors. Int J Urol. 2023 May;30(5):456-462. [IF 2.6, CI 0]
293.

Yamada S, Miyata H, Isono M, Hori K, Yanagawa J, Murai A, Minowa T, Mizue Y,

Sasaki K, Murata K, Tokita S, Nakatsugawa M, Iwabuchi S, Hashimoto S, Kubo T, Kanaseki
T, Tsukahara T, Abe T, Shinohara N, Hirohashi Y, Torigoe T. Cisplatin resistance driverclaspin is a target for immunotherapy in urothelial carcinoma. Cancer Immunol Immunother.
2023 Jul;72(7):2057-2065. [IF 5.8, CI 0]
294.

Yamamoto S, Arakaki R, Noguchi H, Takeda A, Uchishiba M, Kamada S, Mineda A,

Kon M, Kawakita T, Kinouchi R, Yamamoto Y, Yoshida K, Shinohara N, Iwasa T. New
discoveries on the interaction between testosterone and oxytocin in male rats - Testosteronemediated effects of oxytocin in the prevention of obesity. Physiol Behav. 2023 Jul
1;266:114199. [IF 2.9, CI 0]
295.

Iwahara N, Hotta K, Hirose T, Shinohara N. Long-Term Results in Recipients of Late

Conversion to a Calcineurin Inhibitor-Free Regimen with Everolimus After Kidney
Transplantation. Transplant Proc. 2023 May;55(4):803-808. [IF 0.9, CI 0]
296.

Uemura H, Shinohara N, Tomita Y, Nonomura N, Yamada T, Yoshida A, Komoto A.

The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patientswith renal cell carcinoma: results from post-marketing surveillance. Jpn J Clin Oncol. 2023
Jul 31;53(8):730-737. [IF 2.4, CI 0]
297.

Iwahara N, Hotta K, Iwami D, Tanabe T, Tanaka Y, Ito YM, Otsuka T, Murai S,

Takada Y, Higuchi H, Sasaki H, Hirose T, Harada H, Shinohara N. Analysis of T-cellalloantigen response via a direct pathway in kidney transplant recipients with donor-specificantibodies. Front Immunol. 2023 May 3;14:1164794. [IF 7.3, CI 0]298.

Abe T, Yamada S, Kikuchi H, Sazawa A, Katano H, Suzuki H, Takeuchi I, Minami K,

Morita K, Tsuchiya K, Takada N, Maru S, Sato S, Yamashita T, Mochizuki T, Akino T,
Sasaki Y, Shinno Y, Murahashi N, Kawazu T, Furumido J, Miyata H, Matsumoto R, Osawa
T, Murai S, Shinohara N. Impact of postoperative complications on long-term survival in
bladder cancer patients. Jpn J Clin Oncol. 2023 Oct 4;53(10):966-976. [IF 2.4, CI 0]299.

Osawa T, Fujii Y, Kimura G, Kitamura H, Nagashima Y, Iizumi S, Osaka T, Tsubouchi

R, Shinohara N. Electronic patient-reported outcome (e-PRO) monitoring for adverse event
management during cabozantinib treatment in patients with advanced renal cell carcinoma:
protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or
usual care). BMJ Open. 2023 Jul 26;13(7):e070275. [IF 2.9, CI 0]
300.

Blas L, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N,

Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C,
Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y,
Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC Investigators. Clinicalfactors for tumor response, progression, and survival in nivolumab for advanced renal cell
carcinoma in the SNiP-RCC study. Int J Urol. 2023 Sep;30(9):788-796. [IF 2.6, CI 0]
301.

Koyama J, Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T,

Goto T, Osawa T, Nishimura K, Nonomura N, Nishiyama H, Shiraishi T, Ukimura O, Ogawa
O, Shinohara N, Suzukamo Y, Ito A, Arai Y. Sexual function using the EORTC QLQ-TC26
in testicular cancer survivors: A multi-institutional, cross-sectional study. Int J Urol. 2023
Nov;30(11):1044-1050. [IF 2.6, CI 0]
302.

Yagi Y, Kubo Y, Hoshino K, Okada K, Hotta K, Shinohara N, Morimoto Y.

Differences of cerebral oxygen saturation in dialysis patients: a comparison of threeprincipals of near infrared spectroscopy. J Anesth. 2023 Dec;37(6):861-867. [IF 2.8, CI 0]
303.

Kato T, Wang C, Masumori N, Yamasaki T, Matsumoto H, Baba M, Ito K, Kimura T,

Kitamura H, Takahashi M, Hongo F, Hasine K, Eto M, Ikeda JI, Nonomura N, Shinohara N.
T1a Renal Cell Carcinoma With Metastasis: Japanese Society of Renal Cancer Retrospective
Multi-institute Results. Anticancer Res. 2023 Sep;43(9):4061-4065. [IF 2.0, CI 0]
304.

Kusakabe N, Kamijo TC, Wada N, Chiba H, Shinohara N, Miyazato M. Effects of

low-intensity extracorporeal shock wave therapy on lipopolysaccharide cystitis in a rat

model of interstitial cystitis/bladder pain syndrome. Int Urol Nephrol.2024 Jan;56(1):77-86.
[IF 2.0, CI 0]
305.

Togo M, Kitta T, Chiba H, Higuchi M, Kusakabe N, Ouchi M, Abe-Takahashi Y,

Kakizaki H, Shinohara N. Effects of a new selective β3 -adrenoceptor agonist, vibegron, on
bladder and urethral function in a rat model of Parkinson's disease. Low Urin Tract
Symptoms. 2023 Nov;15(6):265-270. [IF 1.3, CI 0]

306.

Minami K, Osawa T, Kojima T, Hara T, Eto M, Takeuchi A, Nakai Y, Ueda K,

Ozawa M, Uemura M, Ohba K, Tamura K, Shindo T, Nakagomi H, Takahashi A,
Anai S, Yokomizo A, Morizane S, Kimura T, Shimazui T, Miyauchi Y, Mitsuzuka K,
Hara H, Yoshimura K, Shiina H, Ito YM, Murai S, Nishiyama H, Shinohara N,
Kitamura H; Japanese Urological Oncology Group. Efficacy and safety of axitinib
for metastatic renal cell carcinoma: Real-world data on patients with renal
impairment. Urol Oncol. 2023 Nov;41(11):458.e9-458.e19. [IF 2.7, CI 0]307.

Takenaka J, Watanabe S, Abe T, Tsuchikawa T, Takeuchi S, Hirata K, Kimura R,

Wakabayashi N, Shinohara N, Kudo K. Predictive factors of early FDG-PET response to[131I] MIBG treatment for unresectable or metastatic pheochromocytomas andparagangliomas (PPGLs). Neuroendocrinology. 2023 Sep 19. doi: 10.1159/000534175. [IF
4.1, CI 0]
308.

Kitta T, Kanno-Kakibuchi Y, Chiba H, Higuchi M, Ouchi M, Togo M, Abe-Takahashi

Y, Tsukiyama M, Shinohara N. Episodes of Febrile Urinary Tract Infections Occur MoreOften in the Winter in Patients with Spina Bifida. Urol Res Pract. 2023 May;49(3):211-215.
[IF NA, CI 0]
309.

Kitta T, Kobayashi S, Togo M, Chiba H, Higuchi M, Kusakabe N, Tsukiyama M,

Ouchi M, Abe-Takahashi Y, Shinohara N. Detrusor-Overactivity-Related Voiding in Women
Mimics Bladder Outflow Obstruction and Conceals Underactivity. Urol Res Pract. 2023
Jul;49(4):266-270. [IF NA, CI 0]
310.

Kikuchi H, Abe T, Miyake M, Miyata H, Matsumoto R, Osawa T, Nishimura N,

Fujimoto K, Inokuchi J, Yoneyama T, Tomida R, Numakura K, Matsushita Y, Matsumoto K,
Sato T, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama
H, Shinohara N. The impact of second transurethral resection on survival outcomes inpatients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin
therapy. Jpn J Clin Oncol. 2024 Feb 7;54(2):192-200. [IF 2.4, CI 0]
311.

Kikuchi H, Maishi N, Yu L, Jia Z, Li C, Sato M, Takeda R, Ishizuka K, Hida Y,

Shinohara N, Hida K. Low-dose metronomic cisplatin as an antiangiogenic and antiinflammatory strategy for cancer. Br J Cancer. 2023 Dec 1. doi: 10.1038/s41416-023-024982. [IF 8.8, CI 0]
312.

Kato T, Nakano Y, Hongo F, Katano H, Miyagawa T, Ueda K, Azuma H, Nozawa M,

Hinata N, Hori J, Otoshi T, Shimizu N, Aizawa M, Osada S, Matsui A, Oya M, Eto M,
Tomita Y, Shinohara N, Uemura H. Real-world outcomes of avelumab plus axitinib as firstline therapy in patients with advanced renal cell carcinoma in Japan: A multicenter,retrospective, observational study (J-DART). Int J Urol 2023 Dec 18. doi: 10.1111/iju.15345.
[IF 2.6, CI 0]
313.

Kusakabe N, Kamijo TC, Wada N, Chiba H, Shinohara N, Miyazato M. Effects of

low-intensity extracorporeal shock wave therapy on lipopolysaccharide cystitis in a rat
model of interstitial cystitis/bladder pain syndrome. Int Urol Nephrol. 2024 Jan;56(1):77-86.
[IF 2.0, CI 0]
314.

Hirose T, Hotta K, Osawa T, Yokota I, Inao T, Tanabe T, Iwahara N, Shinohara N.

Longitudinal mortality risks and kidney functional outcomes in Japanese living kidney
donors. Int J Urol. 2024 Jan 19. doi: 10.1111/iju.15395. [IF 2.6, CI 0]

II.

Review Articles

1. Shinohara N, Koyanagi T. Ras signal transduction in carcinogenesis and progression of
bladder cancer: molecular target for treatment? Urol Res. 2002 Oct;30(5):273-81. [IF NA,
CI 5]
2. Kitta T, Mitsui T, Kanno Y, Chiba H, Moriya K, Shinohara N. Brain-bladder control
network: the unsolved 21st century urological mystery. Int J Urol. 2015 Apr;22(4):342-8.
[IF 2.6, CI 23]
3. Osawa T, Wittmann D, Jimbo M, Keller ET, Namiki S, Abe T, Shinohara N, Skolarus TA.
Providing prostate cancer survivorship care in Japan: Implications from the USA caremodel. Int J Urol. 2016 Nov;23(11):906-915.. [IF 2.6, CI 1]
4. Shibata H, Kato S, Sekine I, Abe K, Araki N, Iguchi H, Izumi T, Inaba Y, Osaka I, Kato S,
Kawai A, Kinuya S, Kodaira M, Kobayashi E, Kobayashi T, Sato J, Shinohara N,
Takahashi S, Takamatsu Y, Takayama K, Takayama K, Tateishi U, Nagakura H, Hosaka M,
Morioka H, Moriya T, Yuasa T, Yurikusa T, Yomiya K, Yoshida M. Diagnosis and treatmentof bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology,
Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society
for Radiation Oncology. ESMO Open. 2016 Mar 16;1(2):e000037. [IF 7.3, CI 36]
5. Kitta T, Kanno Y, Chiba H, Higuchi M, Ouchi M, Togo M, Moriya K, Shinohara N.
Benefits and limitations of animal models in partial bladder outlet obstruction fortranslational research. Int J Urol. 2018 Jan;25(1):36-44. [IF 2.6, CI 18]
6. Osawa T, Takeuchi A, Kojima T, Shinohara N, Eto M, Nishiyama H. Overview of current
and future systemic therapy for metastatic renal cell carcinoma. Jpn J Clin Oncol. 2019 May
1;49(5):395-403. [IF 2.4, CI 22]
7. Ishikawa H, Tsuji H, Murayama S, Sugimoto M, Shinohara N, Maruyama S, Murakami M,
Shirato H, Sakurai H. Particle therapy for prostate cancer: The past, present and future. Int J
Urol. 2019 Oct;26(10):971-979. [IF 2.6, CI 19]
8. Kitta T, Ouchi M, Chiba H, Higuchi M, Togo M, Abe-Takahashi Y, Kusakabe N, Shinohara
N. Animal Model for Lower Urinary Tract Dysfunction in Parkinson's Disease. Int J Mol
Sci. 2020 Sep 7;21(18):6520. [IF 5.6, CI 3]
9. Numakura K, Nakai Y, Kojima T, Osawa T, Narita S, Nakayama M, Kitamura H, Nishiyama
H, Shinohara N. Overview of clinical management for older patients with renal cell
carcinoma. Jpn J Clin Oncol. 2022 Jul 8;52(7):665-681. [IF 2.4, CI 0]
10. Osawa T, Oya M, Okanishi T, Kuwatsuru R, Kawano H, Tomita Y, Niida Y, Nonomura N,
Hatano T, Fujii Y, Mizuguchi M, Shinohara N. Clinical Practice Guidelines for tuberous
sclerosis complex-associated renal angiomyolipoma by the Japanese Urological
Association: Summary of the update. Int J Urol. 2023 Oct;30(10):808-817. [IF 2.6, CI 0]

III.

Books

1. Shinohara N, Togashi M, Takeuchi I, Mori T, Hamada M, Asano Y, Saitoh B, Nakanishi S,
Takamatsu T, Maru A, Koyanagi T: Expression of multi-drug resistance gene product (Pglycoprotein) in normal urothelium and urothelial tumors. pp121-126（Olsson, C.A., SIU
Reports 4;Oncogenes and molecular genetics of urological tumors, Churchill Livingstone,
New York）1992
2. Shinohara N, Ogiso Y, Nonomura K, Koyanagi T, Kuzumaki N: Circumvention of cisplatin
resistance in H-ras transformed-NIH/3T3 cells by suppressor mutant. pp221-227 (Miyazaki
T, Takaku F, and Sakurada K. The Mechanism and New Approach on Drug Resistance ofCancer cells. Excerpta Medica, New York) 1993
3. Shinohara N, Nonomura K, Harabayashi T, Togashi M, Nagamori S, Koyanagi T: Nephronsparing surgery for renal cell carcinoma in von Hippel-Lindau disease. pp48-49 (DeKerinion
J.B, and Howards S. Year Book of Urology 1996. Mosby, St. Louis) 1996
4. Tanaka M, Sazawa A, Shinohara N, Kobayashi Y, Fujioka Y, Koyanagi T, Kuzumaki N.:
Gelsolin gene therapy for human bladder cancer using retrovirus producer cells in nude
mice. pp21-22 (Kuzumaki N. Cytoskeleton and G-proteins in the regulation of cancer,
Hokkaido University Medical Liberary Series Vol. 37, Sapporo) 1998
5. Shinohara N, Koyanagi T: Clinical aspects of kidney cancers in VHL disease. pp183-192(Niimura M, Ohtsuka F, and Hino O. PHACOMATOSIS IN JAPAN, Epidemiology, Clinical
Picture and Molecular Biology; Gann Monograph on Cancer Research, No. 46, Japan
Scientific Societies Press and S.Karger AG,Tokyo) 1999

IV.

Case Reports

1. Ito J, Shinohara N, Koyanagi T, Hanioka K. Ossifying renal tumor of infancy: the firstJapanese case with long-term follow-up. Pathol Int 1998 Feb;48(2):151-9. [IF 2.2, CI 3]
2. Shinohara N, Takeda N, Hiraga H, Demura T, Koyanagi T. The development of a malignant
fibrous histiocytoma after treatment for advanced testicular seminoma. BJU Int 1999
Feb;83(3):355-6. [IF 4.5, CI 0]
3. Haga K, Shinohara N, Harabayashi T, Demura T, Koyanagi T. Is serum hyaluronic acidlevel useful for evaluating the clinical course of malignant mesothelioma of the tunica
vaginalis? BJU Int 1999 Oct;84(6):729-30. [IF 4.5, CI 2]
4. Itoh T, Chikai K, Ota S, Nakagawa T, Takiyama A, Mouri G, Shinohara N, Yamashita T,
Suzuki S, Koyanagi T, Nagashima K. Chromophobe renal cell carcinoma with osteosarcomalike differentiation. Am J Surg Pathol 2002 Oct;26(10):1358-62. [IF 5.6, CI 6]
5. Harabayashi T, Shinohara N, Kakizaki H, Ameda K, Nonomura K, Koyanagi T. Ureteralstricture developing after partial nephrectomy with a microwave tissue coagulator: casereport. J Endourol 2003 Dec;17(10):919-21. [IF 2.7, CI 1]
6. Shinohara N, Nonomura K, Ishikawa S, Seki H, Koyanagi T. Medical management ofrecurrent aggressive angiomyxoma with gonadotropin-releasing hormone agonist. Int J Urol
2004 Jun;11(6):432-5. [IF 2.6, CI 19]
7. Abe T, Shinohara N, Harabayashi T, Tsuchiya K, Suzuki S, Itoh T, Seki T, Togashi M,
Nonomura K, Koyanagi T: Peritoneal carcinomatosis in refractory seminoma. Int J Urol
11(3), 184-186, 2004 [IF 2.6, CI 1]
8. Shinohara N, Harabayashi T, Suzuki S, Nakamura M, Itoh T, Nonomura K: Advanced Renal
Pelvic Carcinoma Associated with Dermatomyositis. Int J Urol 12(10), 906-908, 2005 [IF
2.6, CI 4]
9. Sazawa A, Shinohara N, Harabayashi T, Abe T, Shirato H, Nonomura K: Alternative
approach in the treatment of adrenal metastasis with a real-time tracking radiotherapy inpatients with hormone refractory prostate cancer. Int J Urol 16(4), 410-412, 2009 [IF 2.6, CI
2]
10. Mimura R, Kamishima T, Kubota K, Nakano F, Yabe I, Sasaki H, Maruyama S, Shinohara
N, Harris AA, Haga H, Shirato H, Terae S:Extramedullary plasmacytoma involving perirenal
space accompanied by extramedullary hematopoiesis and amyloid deposition. Jpn J Radiol
28(4), 309-313, 2010 [IF 2.1, CI 2]
11. Aoyagi T, Shinohara N, Kubota-Chikai K, Kuroda N, Nonomura K: Long-term survival inpatient with node-positive adult-onset Xp11.2 translocation renal cell carcinoma. Urol Int
86(4), 487-490, 2011 [IF 1.6, CI 0]

12. Akino T, Shinohara N, Hatanaka K, Kobayashi N, Yamamoto Y, Nonomura K. Successful
penile reconstruction after multimodal therapy in patients with primitive neuroectodermal
tumor originating from the penis. Int J Urol. 2014 Jun;21(6):619-21.. [IF 2.6, CI 2]
13. Matsumoto R, Shinohara N, C-Hatanaka K, Kuroda N, Tsuchiya K, Maruyama S, Abe T,
Nonomura K. Concurrent occurrence of renal cell carcinoma with rhabdoid features in amarried couple: a case report. BMC Res Notes. 2015 Jan 15;8:3. [IF 1.8, CI 0].
14. Iwami D, Ogawa Y, Fujita H, Morita K, Sasaki H, Oishi Y, Higuchi H, Hatanaka K,
Shinohara N. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus
infection in a kidney transplant recipient: A case report. Nephrology (Carlton). 2016 Jul;21
Suppl 1:63-6. [IF 2.5, CI 4]
15. Moriya K, Yamamoto S, Nakamura M, Nishimura Y, Nishida M, Iwai T, Kanno Y, Kitta T,
Shinohara N. Spontaneous Shrinkage of Testicular Teratoma in a Prepubertal Child.
Urology. 2017 May;103:e13-e14. [IF 2.1, CI 1]
16. Nishimura Y, Moriya K, Nakamura M, Kitta T, Kanno Y, Chiba H, Kon M, Shinohara N.
Laparoscopic ureterocalicostomy for ureteropelvic junction obstruction in a 10-year-old
female patient: a case report. BMC Res Notes. 2017 Jul 6;10(1):247. [IF 1.8, CI 3]
17. Takahashi K, Yanagi T, Kitamura S, Hata H, Imafuku K, Iwami D, Hotta K, Morita K,
Shinohara N, Shimizu H. Successful treatment of hidradenitis suppurativa with rituximab
for a patient with idiopathic carpotarsal osteolysis and chronic active antibody-mediatedrejection. J Dermatol. 2018 May;45(5):e116-e117.[IF 3.1, CI 12]
18. Sasaki H, Iwami D, Hotta K, Morita K, Naka T, Shinohara N. Spontaneous reduction ofnative kidney size involving angiomyolipoma lesions in a kidney transplant recipient withtuberous sclerosis complex. Int J Urol. 2018 May;25(5):513-514. [IF 2.6, CI 2]
19. Nakamura M, Moriya K, Kon M, Nishimura Y, Kitta T, Shinohara N. Laparoscopic
nephroureterectomy using the stoma site of cutaneous ureterostomy as a multi-channel portsite in a 15-month-old child with megaureter: A case report. Urology case reports.
2019;27:100990. [IF 0.5, CI 0]

20. Hori K, Hirohashi Y, Aoyagi T, Taniguchi N, Murakumo M, Miyata H, Torigoe T, Abe T,
Shinohara N, Morita K. Abscopal effect following nivolumab induction in a patient withmetastatic renal cell carcinoma-unique pathological features of the primary specimen: A casereport. Exp Ther Med. 2020 Mar;19(3):1903-1907.. [IF 2.7, CI 5]
21. Furumido J, Osawa T, Kikuchi H, Matsumoto R, Abe T, Takakuwa E, et al. Retroperitoneal
extragonadal germ cell tumor without distant metastasis: a case report. International cancer
conference journal. 2020;9(1):5-8. [IF , CI ]22. Shinohara N. New year's greetings. International journal of urology 2020;27(1):5. [IF 2.6,
CI 0]
23. Yamada S, Hotta K, Takahata M, Iwami D, Sugito Y, Tanabe T, Iwahara N, Shinohara N.
Femoral nerve palsy following kidney transplantation: A case report and review of theliterature IJU Case Rep. 2020 Jul 29;3(6):248-251. [IF NA, CI 1]
24. Shinohara N. New year's greetings. Int J Urol. 2021 Jan;28(1):5. doi: 10.1111/iju.14479.
[IF 2.6, CI 0]
25. Shinohara N. IJU this issue. Int J Urol. 2021 Aug;28(8):785. [IF 2.6, CI 0]
26. Kusakabe N, Kitta T, Chiba H, Higuchi M, Shinohara N. A case of pubic osteomyelitis
after implantation of an artificial urinary sphincter: A case report. Low Urin Tract Symptoms.
2022 Jan;14(1):78-81. [IF 1.3, CI 0]
27. Iwahara N, Abe T, Nagai S, Yoshino M, Saito H, Okada H, Kikuchi H, Matsumoto R,
Osawa T, Shinohara N. Postoperative thyroid storm after radical nephrectomy for renal cell
carcinoma with inferior vena cava tumor thrombus. IJU Case Rep. 2021 Jul 13;4(5):330-332.
[IF NA, CI 0]
28. Konno M, Osawa T, Hotta K, Shimizu A, Abe T, Matsumoto R, Kikuchi H, Shinohara N.
Primary renal leiomyosarcoma with a tumor thrombus in the inferior vena cava. IJU Case
Rep. 2021 Nov 19;5(1):66-69. [IF NA, CI 0]
29. Takeda H, Matsumoto R, Takakuwa E, Hori K, Moriguchi T, Yamada S, Kikuchi H, Osawa
T, Abe T, Shinohara N. Favorable response to pembrolizumab in granulocyte colony-stimulating factor-producing upper urinary tract urothelial carcinoma. IJU Case Rep. 2021
Dec 17;5(2):108-112. [IF NA, CI 0]
30. Hayashi A, Yamamoto I, Kawabe M, Kobayashi A, Ito M, Hotta K, Shinohara N, Tasaki T,
Yokoo T, Iwami D. CASE REPORT: Serial Cases of False-Positive Flow- Cytometry T Cell
Crossmatch Associated With Anti-Blood Type Antibodies in Patients Undergoing ABOIncompatible Kidney Transplantation. Front Immunol. 2022 Mar 10;13:862652. [IF 7.3, CI
0]
31. Takayanagi A, Kato F, Nozaki A, Matsumoto R, Osawa T, Kuwahara K, Matsuno Y, Asano
H, Kato T, Watari H, Abe T, Shinohara N, Kudo K. Imaging findings of ovarian metastasisof primary renal cell carcinoma: A case report and literature review. Radiol Case Rep. 2022
May 5;17(7):2320-2327. [IF NA, CI 0]
32. Yamagata Y, Abe T, Iwahara N, Takada K, Hida Y, Takakuwa E, Kikuchi H, Matsumoto R,
Osawa T, Shinohara N. Metastatic neuroendocrine carcinoma of right adrenal gland
successfully treated with laparoscopic adrenalectomy after multimodal therapy. IJU Case
Rep. 2022 Jul 29;5(6):446-450. [IF NA, CI 0]
33. Shinohara N. This Issue 30-5. Int J Urol. 2023 May;30(5):421. doi: 10.1111/iju.15186. [IF
2.6, CI 0]
34. Nonoyama S, Hotta K, Iwahara N, Tanabe T, Hirose T, Harada S, Junichi S, Nakazawa D,
Shigematsu A, Otsuka T, Shinohara N. Use of Mixed Lymphocyte Reaction Assay to
Evaluate Immune Tolerance before Kidney Transplantation with an ImmunosuppressionFree Protocol following Hematopoietic Stem Cell Transplantation from the Same Donor.
Nephron. 2023;147(10):621-626. [IF 2.5, CI 0]
35. Otsuka T, Tanabe T, Hotta K, Iwasaki S, Tsuji T, Takahashi A, Takakuwa E, Shinohara N,
Matsuno Y. Exacerbation of Intimal Fibrosis and Endarteritis in a Kidney Transplant
Recipient with Chronic Active Antibody-Mediated Rejection and COVID-19: A Case Report.
Nephron. 2023;147 Suppl 1:41-45. [IF 2.5, CI 0]
36. Hosokawa C, Hotta K, Okamoto T, Cho Y, Hirose T, Iwahara N, Manabe A, Shinohara N.
Prophylactic bilateral nephrectomy and preemptive kidney transplantation for Denys-Drash

syndrome prior to development of kidney failure. Pediatr Nephrol. 2024 Mar;39(3):905-909.
[IF 3.0, CI 0]
37. Iesaka H, Kameda H, Miya A, Nomoto H, Cho KY, Nakamura A, Abe T, Shinohara N,
Atsumi T. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune
checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
Medicine (Baltimore). 2023 Dec 22;102(51):e36664. [IF 1.6, CI 1]

V．Presentation in Meeting
特別講演
1. Shinohara N: Retroperitoneal laparoscopic partial nephrectomy with ice slush cooling
5th Urologic Oncology Seminar in Quangzoung, Quangzong, 2010
2. Shinohara N: The role of metastasectomy for patients with metastatic urological cancer
28th Korea-Japan Urological Congress, Swon, 2011
3. Shinohara N: Regional differences in the approach to systemic therapy for metastatic renal
cell carcinoma: The Asian approach, 32th SIU annual meeting in FUKUOKA, Fukuoka,
2012
教育講演
1. Shinohara N: The role of cytoreductive nephrectomy for patients with metastatic renal cell
carcinoma
Educational Seminar, 27th Japan-Korea Urological Congress, Kyoto, 2010
2. Shinohra N: “Public speaking”, Educational Lecture, Advancements in Urology 2011
(AUA/JUA joint meeting), Honolulu, 2011.
3. Shinohara N: “Medical Writing”, UAA Youth section, 9th Asian Endurological Conference,
Kathomandu, 2011.
4. Shinohara N: Sorafenib-associated Hand-Foot Skin Reaction: How to deal with thisadverse event?, Evening seminar, 4th Congress of the World Union of Wound Healing
Societies, Yokohama, 2012
5. Shinohara N: Assessing the response to targeted therapies in renal cell carcinoma.
Lecture 2. AUA/JUA International affiliate society meeting New Orleans 2015.
6. Shinohara N: What we have been doing on immune-oncology at clinical research andpractice ” Renal cell carcinoma” Educational lecture. Oncology Summit Japan Tokyo2015
シンポジウム1.

Shinohara N: Psycological distress of urologic cancer patients in Japan-Based on HAD
test, Special Satellite Symposium, Pan-Pacific Conference of the International Society for
Quality of Life Research. Tokyo, 2001

2.

Shinohara N: The role of cytoreductive nephrectomy for patients with metastatic renal cell
carcinoma. Symposium 1, JUA/AUA Joint meeting in AUA 2011(Symposium 1),
Washington DC, 20113.

Shinohara N: Treatment of patients with metastatic bladder cancer “unfit” for cisplatinbased chemotherapy , Symposium 10 (Kidney and Bladder Cancer), 6th Japan-Asean
Conference on Men’s Health & Aging, Kamakura, 20114.

Shinohara N: Castration-resistant prostate cancer =Current status and future perspectives
in Japan=. Symposium(Therapeutic approaches in the management of castration-resistant
prostate cancer), The 29th Japan-Korea Urological Congress, Kagoshima, 20125.

Shinohara N: =prognostic factor=, Symposium (Treatment strategy of RCC in Japan), The
32th SIU annual meeting in FUKUOKA, Fukuoka, 2012

6.

Shinohara N: The role of metastasectomy for patients with metastatic renal cell carcinoma.
Symposium (Contemporary Asian urology session), The 101th Japanese Urological
Association annual meeting, Sapporo, 2013

一般発表
1. Shinohara N, Togashi M, Takeuchi I, Mori T, HamadaM, Asno Y, Saito B, Nakanishi S,
Takamatsu T, Maru A, Koyanagi T: Expression of multi-drug resistance gene product (Pglycoprotein) in normal urothelium and urothelial tumors. SIU 22nd Congress, Sevillia,
1991
2. Shinohara N, Nonomura K, Kobayashi S, Koyanagi T: Serum and urine catecholamines inadrenal incidentaloma. 9th Japan-Korea Urological Congress, Tokyo, 1992.
3. Shinohara N, Ogiso Y, Nonomura K, Koyanagi T, Kuzumaki N: Circumvention of cisplatin
resistance in H-ras transformed NIH/3T3 cells by suppressor mutant. International
Symposium of The Mechanism and New approach on Drug Resistance of Cancer Cells,
Sapporo, 1992.

4. Shinohara N, Nonomura K, Nagamori S, Koyanagi T: Expression of multi-drug resistancegene product (P-glycoprotein) in renal pelvic and ureter tumors.

AUA 88th Annual

Meeting, San Antonio, 1993.
5. Shinohara N, Tanaka M, Nagamori S, Takakura F, Seki T, Nonomura K, Koyanagi T,
Togashi M, Maru A: Prohylactic chemotherapy with anthracycline (adriamycin, epirubicin,
and THP) for primary superficial bladder cancer. 5th International Conference on
Treatment of Urinary Tract Tumors with Adriamycin/ Farmorubicin, Hakone, 1993.
6. Shinohara N, Nonomura K, Harabayashi T, Hamada M, Kawakura K, Ueno H, Koyanagi
T: Expression of proliferating cell nuclear antigen (PCNA) in normal prostate, benign
prostatic hypertrophy and prostatic carcinoma.

8th SBUR annual meeting, San Francisco,

1994.
7. Shinohara N, Nonomura K, Tanda K, Nagamori S, Togashi M, Koyanagi T: Growth patternof renal lesions after conservative surgery for renal cell carcinoma in von Hippel-Lindau
disease. SIU 23rd Congress, Sydney, 1994.
8. Shinohara N, Ogiso Y, Tanaka M, Sazawa A, Demura T, Nonomura K, Koyanagi T.:
Growth suppression of renal cell carcinoma cell lines by a dominant negative H-ras mutant.
1st World Congress on Basic Urological Research Organized by the ESUOE and SBUR.
Rotterdam. 1995.
9. Shinohara N, Tanaka M, Sazawa A, Demura T, Nonomura K, Koyanagi T.: Growth
suppression of renal cell carcinoma cell lines by a dominant negative H-ras mutant. AUA
91th Annual Meeting. Orlando. 1996.
10. Shinohara N, Nagamori S, Demura T, Nounaka O, Omuro H, Nonomura K, Koyanagi T: 5fluorouracil and low dose interferon alpha-2a in patients with hormone-refractory prostatecancer. AUA 91th Annual Meeting. Orlando. 1996.
11. Shinohara N, Sazawa A, Demura T, Nonomura K, Koyanagi T: Nephron-sparing operation
for renal cell carcinoma in von Hippel-Lindau disease. 2nd International VHL symposium,
Honoruru, 1996

12. Shinohara N, Sazawa A, Demura T, Nonomura K, Koyanagi T.: Nephron-sparing surgery
for renal cell carcinoma in von Hippel-Lindau disease. 13th Japan-Korea Urological
Congress. Osaka. 1996.
13. Shinohara N, Sazawa A, Tanaka M, Demura T, Nonomura K, Koyanagi T: overexpressionof ras guanine nucleotide exchange factor, son of sevenless protein, in bladder cancer. AUA
92nd Annual Meeting. New Orleans. 1997.
14. Shinohara N, Seki T, Demura T, Nonomura K, Koyanagi T.: Treatment strategy for renal
cell carcinoma in von Hippel-Lindau disease. SIU 24th Congress. Montreal. 1997
15. Shinohara N, Tsuchiya K, Harabayashi T, Enami N, Tanaka M, Seki T, Demura T,
Nonomura K, Koyanagi T: Nephron sparing surgery in patients with localized small renal
cell carcinoma. SIU 24th Congress. Montreal. 1997
16. Shinohara N, Demura T, Nonomura K, Koyanagi T: Treatment of renal cell carcinoma invon Hippel-Lindau disease. UICC Symposium: Familial Cancer and Prevention, Kobe.
1997
17. Shinohara N, Harabayashi T, Sazawa A, Tanaka M, Kobayashi Y, Demura T, Koyanagi T:
The significance of C3G, one of ras guanine nucleotide exchange factors, in the
proliferation of human bladder cancer cell lines. AUA 93rd Annual Meeting. San Diego.
1998
18. Shinohara N, Watanabe T, Sazawa A, Harabayashi T, Kuzumaki N, Koyanagi T: The
significance of ras guanine nucleotide exchange reaction in bladder cancer cell lines, 4thInternational Symposium; Impact of biotechnology on cancer prediction, prevention andtreatment, Nice. 1998
19. Shinohara N, Harabayashi T, Sato S, Sakamoto K, Hioka T, Demura T, Koyanagi T: The
impact of neohron-sparing surgery on quality of life in patients with localized kidneycancer, AUA 94th Annual Meeting, Dallas, 1999.
20. Shinohara N, Watanabe T, Sazawa A, Harabayashi T, Koyanagi T, Kuzumaki N: In vivo
adenovirus-mediated gene therapy of human bladder cancer in orthotopic model by thedominant negative ras mutant, AUA 95th Annual Meeting, Atlanta, 2000

21. Shinohara N, Watanabe T, Sazawa A, Harabayashi T, Koyanagi T, Kuzumaki N:
Adenovirus-mediated gene therapy of human bladder cancer in orthotopic model by thedominant negative ras mutant N116Y, 5h International Symposium on Predictive Oncology& Therapy; Impact of Biothechnology on Cancer Diagnosis & Prognostic Indicators,
Geneva, 2000
22. Shinohara N, Harabayashi T, Sazawa A, Kitamura K, Shirato H, Koyanagi T: Conformal
radiotherapy with or without concurrent infusion chemotherapy for locally-advanced
bladder cancer: results of a pilot study. Gated Radiotherapy 2000, Sapporo, 2000
23. Shinohara N, Harabayashi T, Koyanagi T: Stage-specific followup protocol after radical
nephrectomy for renal cell carcinoma: Could we follow the T1b patients by a same
followup protocol of T1a patients?

AUA 97th Annual Meeting, Atlanta, 2002

24. Shinohara N: Clinical features and prognosis of renal cell carcinoma in Japanese patientswith von Hippel-Lindau disease. International VHL conference, Kohchi, 2004
25. Shinohara N, Nishi M, Shibata Y, Minowada S, Murakumo M, Furuno T, Yamanaka H,
Koyanagi T: A new portable flexible cystoscope with bullet-tip: Is this less uncomfortable
than standard flexible cystoscope? 27thth Congress of the Societe Internationale’d Urologie,
Hawai, 2004
26. Shinohara N, Suzuki S, Abe T, Murakumo M, Nagamori S, Mitsuhashi K, Harabayashi T,
Nonomura K：Salvage chemotherapy with paclitaxel, ifosfamide and nedaplatin (PIN
regimen) in patients with urothelial cancer who have received prior cisplatin-based therapy.
20th European Association of Urology Congress, Istanbul, 2005
27. Shinohara N, Suzuki S, Harabayashi T, Murakumo M, Mitsuhashi K, Demura T, Nagamori
S, Nonomura K: Combination chemotherapy paclitaxel, ifosfamide and nedaplatin in thetreatment for advanced or recurrent urothelial cancer. 41st ASCO annual meeting, Orlando
2005
28. Shinohara N, Suzuki S, Abe T, Sazawa A, Harabayashi T, Nonomura K: Salvage
chemotherapy with paclitaxel, ifosfamide and nedaplatin in patients with urothelial cancer
who have received prior cisplatin-based therapy. 100th AUA Annual meeting, San Antonio

2005
29. Shinohara N, Harabayashi T, Suzuki S, Nagao K, Seki H, Murakumo M, Mitsuhashi K,
Demura T, Nagamori S, Matsuyama H, Naito K, Nonomura K: Combination chemotherapy
with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who hadreceived prior cisplatin-based therapy; advanced report. 21th EAU Annual Congress Paris
2006
30. Shinohara N, Harabayashi T, Suzuki S, Nagao K, Nagamori S, Matsuyama H, Naito K,
Nonomura K: Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patientswith urothelial cancer who had received prior cisplatin-based therapy. 42th ASCO annual
meeting Atlanta 2006
31. Shinohara N, Harabayashi T, Sazawa A, Abe T, Takeuchi I, Kumagai A, Kashiwagi A,
Nagamori S, Nonomura K: Positive impact of nephron-sparing surgery on long-term
postoperative quality of life in patients with T1 renal cell carcinoma. 101th AUA annual
meeting Anaheim 2007
32. Shinohara N, Harabayashi T, Sazawa A, Watarai Y, Kumagai A, Murakumo M, Sakashita
S, Mori T, Kanagawa K, Nonomura K: Meloxicam, a selective cyclooxygenase-2 (COX-2)
inhibitor, enhances the response to interferon-α2a in metastatic renal cell carcinoma: a phase
II study on efficacy and toxicity. ASCO annual meeting Chicago 2007
33. Shinohara N, Harabayashi T, Sazawa A, Nonomura K, Hokkaido Immunotherapy ResearchGroup: Combination therapy of meloxicam, a COX-2 inhibitor, and interferon alfa inmetastatic renal cell carcinoma. ASCO-GU meeting San Franscico 2008.
34. Shinohara N, Kumagai A, Kanagawa K, Watarai Y, Murakumo M, Sazawa A, Abe T,
Harabayashi T, Nonomura K, Hokkaido Immunotherapy Research Group: Phase II trial of
meloxicam, a COX-2 inhibitor, and interferon alfa in patients with metastatic renal cell
carcinoma. ASCO 44th annual meeting Chicago 2008.
35. Shinohara N, Sazawa A, Uchino H, Abe T, Maruyama S, Morita K, Sato S, Suzuki S,
Harabayashi T, Nonomura K: New treatment approach for poor-risk patients with metastatic
renal cell carcinoma: Is upfront interferon-alfa therapy feasible on the identification of
appropriate candidate for cytoreductive nephrectomy?. 5th ASCO-GU meeting Orlando

2009.
36. Shinohara N, Nonomura N, Kimura G, Eto M, Minami H, Yamazaki N, Naito S: A
randomized multi-center phase II trial on efficacy of high-slip skin care pad for hand-footskin reaction caused by sorafenib in patients with renal cell carcinoma. 47th ASCO annual
meeting Chicago 2011.
37. Shinohara N, Abe T, Mochizuki T, Kashiwagi A, Kanagawa K, Maruyama S, Sazawa A,
Oba K, Nonomura K: Prognosis of renal cell carcinoma patients with disease recurrence
following nephrectomy for localized disease.

8th ASCO-GU meeting San Francisco 2012.

38. Shinohara N, Abe T, Maruyama S, Sazawa A, Nonomura K: Risk classification to predictsurvival after cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.
107th AUA annual meeting in Atlanta Atlanta 2012
39. Shinohara N, Maruyama S, Shimizu S, Nonomura K, Shirato H: Longitudinal comparisonof quality of life after real-time tumor-tracking intensity-modulated radiation therapy andradical prostatectomy in patients with localized prostate cancer. 3rd International
conference on real-time tumor-tracking radiation therapy with 4D molecular imaging
technique Sapporo 2013
40. Shinohara N, Nonomura N, Kimura G, Eto M, Minami H, Yamazaki N, Naito S: A
randomized multi-center phase II trial on efficacy of a hydrocolloid dressing containing
ceramide with a low-friction external surface for hand-foot skin reaction caused bysorafenib in patients with renal cell carcinoma. The 49th ASCO Annual meeting Chicago
2013.
その他
1. Shinohara N, Suzuki S, Harabayashi T, Murakumo M, Mitsuhashi K, Demura T, Nagamori
S, Nonomura K: Combination chemotherapy with paclitaxel, ifosfamide, and nedaplatin in
the treatment for advanced or recurrent urothelial cancer. J Clin Oncol, 2005 ASCO Annual
Meeting Proceedings Vol 23, 2007: 5105
2. Shinohara N, Harabayashi T, Suzuki S, Nagao K, Nagamori S, Matsuyama H, Naito K,
Nonomura K: Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patientswith urothelial cancer who had received prior cisplatin-based therapy. J Clin Oncol, 2006

ASCO Annual Meeting Proceedings Vol 24, 2006: 236
3. Shinohara N, Harabayashi T, Sazawa A, Nonomura K, Watarai Y, Kumagai A, Murakumo
M, Kanagawa K, Sakashita S: Combination therapy of meloxicam, a selective COX-2
inhibitor, and interferon alfa in metastatic renal cell carcinoma: A phase II study on efficacy
and toxicity. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Vol 25, 2007: 5105
4. Shinohara N, Abe T, Sazawa A, Nonomura K: Phase II trial of meloxicam, a COX-2
inhibitor, and interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol,
2008 ASCO Annual Meeting Proceedings Vol 26, 2008: 16003
5. Shinohara N, Nonomura N, Kimura G, Eto M, Minami H, Yamazaki N, Naito S: A
randomized multicenter phase II trial on efficacy of high-slip skin care pad for hand-footskin reaction caused by sorafenib in patients with renal cell carcinoma. J Clin Oncol, 2011
ASCO Annual Meeting Proceedings Vol 29, 2011: TPS233
6. Shinohara N, Nonomura N, Kimura G, Eto M, Minami H, Yamazaki N, Naito S: A
randomized multicenter phase II trial on efficacy of a hydrocolloid dressing containing
ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenibin patients with renal cell carcinoma. J Clin Oncol, 2013 ASCO Annual Meeting Proceedings
Vol 31, 2013: TPS233 31, 2013: 9623
7. Shinohara N: Editorial Comment to Features, risk factors and clinical outcome of "verylate" recurrences after surgery for localized renal carcinoma: A retrospective evaluation of acohort with a minimum of 10 years of follow up. Int J Urol. 2016; 23(1):40-41. [5y-IF:
1.932]

VI 日本語ガイドライン等
1. 腎癌診療ガイドライン 2007 年版 金原出版 日本泌尿器科学会編 （作成委員）
2. 腎癌診療ガイドライン 2011 年版 金原出版 日本泌尿器科学会編 （作成委員）
3. 精巣腫瘍診療ガイドライン 2015 年版 金原出版 日本泌尿器科学会編 （作成委員）
4. 結節性硬化症に伴う腎血管筋脂肪種診療ガイドライン 2016 年版 金原出版 日本泌尿器科学会・日本結節性硬化症学会、編 （作成委員）
5. 結節性硬化症に伴う腎血管筋脂肪種診療ガイドライン 2023 年版 メディカルレビュー社
日本泌尿器科学会・日本結節性硬化症学会、編 （作成委員長）
6. 腎盂・尿管癌診療ガイドライン 2023 年版 医学図書出版 日本泌尿器科学会編（評価委員長）
7. 骨転移診療ガイドライン 第１版 南江堂 日本臨床腫瘍学会、編 （作成委員）
8. フォン・ヒッペル・リンドウ（VHL）病診療ガイドライン 「 フォン・ヒッペル・リンドウ病の病態調査と診断治療系確立の研究」班 中外医学社 （研究分担者）
9. 腎癌取り扱い規約 第 4 版（2011 年４月） 金原出版 日本泌尿器科学会・日本病理学会・日本医学放射線学会編 （作成委員）
10. 腎癌取り扱い規約 第 5 版（2020 年 12 月） メディカルレビュー社 日本泌尿器科学会・
日本病理学会・日本医学放射線学会編 （作成委員長）
11. 精巣腫瘍取り扱い規約 第 4 版（2018 年 8 月） 金原出版 日本泌尿器科学会・日本病理学会・日本医学放射線学会・日本臨床腫瘍学会、編 （作成委員）
12. がん治療認定医教育セミナー 第８版 一般社団法人日本がん治療認定医機構教育委員会
13. がん治療認定医教育セミナー 第 9 版 一般社団法人日本がん治療認定医機構教育委員会

14. がん治療認定医教育セミナー 第 10 版 一般社団法人日本がん治療認定医機構教育委員会

VII 受賞・表彰・研究費
名目

受賞年月

助成金

1995/11/2

選考機関

秋山記念生命科
学振興財団

受賞名

助成金

2000/4/11

ライフサイエンス

900,000円

題名

ヒト腎細胞がんに対する N116Yを用いた遺伝子治療の基礎的研究
泌尿器科がん患者における精財団法人聖ルカ・
助成金

受賞金額

助成金

研究所

500,000

神症状の評価と、それに基づく

円

看護アプローチの樹立に関する研究
遠隔転移を有する腎がん患者表彰

2008/10/31

第４６回日本癌治
療学会総会

優秀演題

に対する天然型インターフェロ
ン、メロキシカム併用療法の意
義前腕遊離皮弁を用いた陰茎形

表彰

2012/6/16

第９回泌尿器科再建再生研究会

研究会賞

成術により陰茎の再建に成功した陰茎原発 primitive
neuroectodermal tumor の１例

表彰

表彰

2013/10/2426

第５１回日本癌治療学会総会

2019/10/5

北海道医師会

Sorafenib 関連手足皮膚反応に
優秀演題

対する高すべり性スキンケアパ
ッドの有用性の検討

北海道医師会賞

進行性腎細胞がんにおける予後因子の解析と全身療法の適正使用に関する研究
進行性腎細胞がんにおける予表彰

2019/10/5

北海道

北海道知事賞後因子の解析と全身療法の適正使用に関する研究

表彰

2021/4/21

厚生労働省

厚生労働大臣令和２年度臓器移植対策推進

感謝状

功労者

Ⅷ. 医局の変遷